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MESENCHYMAL STEM CELL RESCUE FOR BONE FORMATION  
FOLLOWING STEREOTACTIC RADIOTHERAPY OF OSTEOSARCOMA 
 
Background: Osteosarcoma (OSA) is the most common form of primary bone cancer in 
dogs and humans.  Curative-intent treatment options include amputation, radiation therapy or 
surgical limb salvage for local tumor control combined with adjuvant chemotherapy for 
prevention or delay of metastatic disease. Stereotactic radiotherapy (SRT) delivers high dose per 
fraction radiation to a defined tumor volume with relative sparing of surrounding normal tissues. 
It has been successfully used as a non-surgical limb salvage procedure to achieve local tumor 
control of spontaneous OSA in dogs. The most common complication observed with this 
treatment is pathologic fracture of the irradiated bone.  Mesenchymal stem cells (MSCs) are 
multipotent stem cells that have the capability to differentiate into many cell types including 
bone.  The ability of MSCs to differentiate into bone suggests that they should be investigated as 
a potential therapy to regenerate bone in SRT treated bone.  
 
Methods: In experiments described herein, we developed an orthotopic model of canine 
osteosarcoma in athymic rats and evaluated the ability of SRT to achieve local tumor control. We 
then evaluated the ability of MSCs to regenerate bone after SRT treatment of OSA. 
 
Results: We demonstrated that the canine OSA cell line reliably engrafted in the rat 




replicate a clinical scenario to test MSC behavior following SRT of OSA. Two weeks after OSA 
cell inoculation was identified as the time period when the same clinical characteristics were 
observed as in canine OSA cases and was chosen to be an appropriate time for SRT treatment.  
The optimal SRT protocol to achieve local tumor control while minimizing acute radiation 
effects was determined to be 3 fractions of 12 Gy delivered on consecutive days. MSCs 
administered either intravenously or intraosseously 2 weeks after SRT revealed no new bone 
formation; however, decreased tumor necrosis was observed after MSC treatment.  
 
Conclusion: The results herein describe the characterization of an orthotopic rat model of 
canine OSA. This model was useful for the evaluation of different dose and fractionation SRT 
protocols along with combination adjuvant therapies that may be clinically relevant for canine or 
human OSA. The administration of MSCs following SRT did not induce new bone growth. The 
lack of efficacy is most likely due to the radiation-induced alterations to the bone 
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 Osteosarcoma (OSA) is the most common primary bone tumor in dogs accounting for 
85% of all canine bone cancers (1, 2).  It is estimated that more than 8000 dogs are diagnosed 
with OSA each year in the United States (2). Osteosarcoma has been described as one of the 
most aggressive tumors in canines as it is both locally destructive and has a high metastatic rate. 
The onset of OSA (middle aged dogs) peaks at age 7 and older, with a secondary peak between 
18 and 24 months of age indicating a bimodal age distribution (3). Osteosarcoma occurs 
predominantly in giant and large breeds such as Saint Bernards, Golden Retrievers, Greyhounds, 
German Shepherds, Dobermans and Great Danes. Large and giant breed dogs have a sixty-fold 
greater risk of developing OSA than smaller breeds (4). Less than 5% of all OSA cases are 
diagnosed in dogs weighing less than 15 kilograms (2). It is also more prevalent in males than 




 The etiology of spontaneous canine OSA is not completely understood. Several studies 
suggest that canine OSA may be caused by large breed predisposition, trauma or gene mutations.  
Canine OSA is most commonly seen in the metaphyseal regions of weight-bearing bones of the 




trauma to the physeal regions resulting in mutagenic signals (5). Genetic mutations have been 
widely reported as contributors to various canine tumors including OSA. For example, mutations 
of p53, a critical regulator of cell proliferation, are thought to play an active role in the 
progression of OSA (6, 7). Other reported initiating environmental events associated with the 
development of OSA in dogs include fracture, metallic implants, chronic osteomyelitis, and 
ionizing radiation (2, 5, 8-10).   
 
Presentation, Diagnosis & Prognosis 
 
Osteosarcoma can occur in any bone; however, about 75 % cases occur in the 
appendicular skeleton with the remaining 25% in the axial skeleton (5). Osteosarcoma occurs in 
the forelimbs twice as often as the hind limbs (5).  This is because the forelimbs bear 
approximately 60% of the animal’s body weight and weight-bearing bones have been shown to 
be preferentially affected by OSA over non-weight-bearing bones (5). The metaphyseal regions 
of the distal radius and proximal humerus are the most commonly affected sites in the forelimbs. 
OSA is comprised of spindle shaped mesenchymal cells that produce osteoid resulting in erratic 
and aggressive bone formation (11). The clinical characteristics observed in dogs with OSA 
include chronic lameness, local lysis of the affected bone, abnormal proliferation of bone and 
pathologic fracture. The radiographic characteristics of the OSA lesion are a mixed lytic-
productive pattern. Histology of a biopsy of the affected bone or resected surgical specimen is 
required to make a definitive diagnosis (2).  The biopsy is comprised of disorganized spindle 
shaped cells with excess production of osteoid (2). Microscopic tumor metastases are presented 




via hematogenous metastatic routes (11). The most common sites of metastasis are the lungs and 
other bones. Macroscopic evidence of pulmonary metastasis is observed in approximately 10% 
of dogs at the time of diagnosis; yet lung metastases cause approximately 90% of all OSA deaths 
in dogs (5, 12). The presence of visible lung metastasis at the time of diagnosis is a poor 
prognostic indicator; with a reported median survival of 100 to 130 days (13, 14). Bone 
metastases are observed in ~7% of dogs at the time of diagnosis (15). Metastases to regional 
lymph nodes have been observed in about 4% of dogs at the time of diagnosis and are also 
associated with a poor prognosis (16).  
 
Relevant Translational Model 
 
Osteosarcoma is also the most common form of primary bone cancer in humans 
accounting for approximately 35% of all bone tumors (17). More than 900 new cases are 
diagnosed each year in the United States (18). It is most prevalent in children during the second 
decade of life and in individuals greater than 60 years of age (17, 19). Human and canine OSA 
have several distinct similarities making canine spontaneous OSA models ideal for evaluating 
novel treatments for primary and metastatic tumor control in humans. Tumor biology and size at 
presentation histology are almost indistinguishable between human and canine OSA (2, 20). 
Tumors occur in weight-bearing bones in both species with similar bimodal susceptible age 
distribution; however, OSA is more prevalent in adolescents whereas in canines it is observed 
most commonly in middle-aged to older dogs (2, 3).  Both are exposed to similar environmental 
risk factors as they inhabit similar environments (2). Human and canine OSA has been reported 




tumors in rodent models, canine OSA is spontaneous and behaves biologically similar to that in 
humans with the most common sites of metastases to bones and the lungs. The similarities 
described herein make spontaneous OSA in dogs an excellent large animal translational model 




Treatment regimens for canine OSA can be broadly divided into palliative and curative-
intent options (1).  
 
Palliative-intent Treatment  
 
The aim of palliative management is to decrease pain and lameness. Palliative treatment 
is indicated for dogs that present with metastatic disease or when the owners do not want to 
pursue curative-intent treatment options. The goal of this type of treatment is to improve the 
quality of life for the dog but will not provide increased survival time nor provide long-term 
local tumor control. Palliative therapy options include oral analgesics, external beam radiation 
therapy, bisphosphonates, and limb amputation.  
 
Palliative radiotherapy (XRT) of canine OSA decreases pain by reducing local tumor site 
inflammation and delaying local disease progression, thus improving the animal’s quality of life 
(5). Treatment involves administration of coarsely fractionated doses of ionizing radiation, such 




delivered on two consecutive days to the primary tumor (21, 22).  At these radiation doses, 
adjacent normal tissue will recover from sub-lethal doses of radiation whereas the tumor will 
have more severe inhibitory effects due to its relative radiosensitivity (23). Side effects to normal 
tissues are typically minimal with palliative XRT.  However, at these dosages, desirable long-
term tumor control is not achieved resulting in eventual tumor progression. Increasing total 
radiation dosage along with the combination of anti-inflammatory analgesics can improve the 
response duration.  Bisphosphonates, which inhibit tumor-associated bone resorption by inducing 
osteoclast apoptosis, can be administered alone or in conjunction with other palliative modalities 
to decrease pain and incidence of pathologic fracture (24-26). Acute radiation side effects are 
minimal and a median survival time ranging of 122 to 313 days has been reported with palliative 
treatments that include radiation alone or in combination with bisphosphonates (21, 27).  
 
Dogs that are unresponsive to palliative radiation therapy or that have pathologic fracture 
are potential candidates for palliative amputation. Amputation, when used for palliative therapy, 
removes the source of tumor-associated bone pain and the majority of dogs function well on 
three legs. After amputation surgery alone, the median survival time is between 103 and 175 




Curative-intent treatment of osteosarcoma is directed at achieving complete tumor control 
of the primary bone lesion and delaying or preventing the onset of metastatic disease. Even 




this disease. Approximately 90% of dogs still die within 3 years of diagnosis due to the highly 
metastatic nature of OSA (5). Treatment options with curative-intent include amputation or limb 
sparing surgery for local tumor control followed by adjuvant chemotherapy for systemic disease. 
Other treatment options include the use of immunomodulators and high dose radiation therapy 
(5).  
 
Amputation followed by chemotherapy is the most common procedure used for curative 
intent treatment of OSA (30).  This option removes the primary tumor with radical margins, 
while eliminating the risk of pathologic fracture and tumor associated bone pain. The surgical 
procedure is well tolerated, has a low complication rate and most dogs function very well after 
amputation (5, 30). Limb sparing surgery is a treatment option for animals that are poor 
candidates for amputation due to concurrent severe osteoarthritis, neurological diseases or owner 
unwillingness for amputation (5). This procedure involves surgical resection of the tumor and 
reconstruction of the resultant bone defect with an allograft bone or metallic endoprosthestic 
spacer that is fixed to the host bone (31-33). The distal radius has been shown to be the most 
ideal and reliable site for limb salvage (34). Complications associated with surgical limb salvage 
are high and include implant loosening, infection and local tumor recurrence (31, 32). These 
common complications may result in revision surgeries or amputation (1, 32, 34, 35).  About 
20% of dogs experience local tumor recurrence which can be treated by further surgery or 
amputation without decreasing median survival time (32).  Nearly 40% of all limb sparing 
surgeries become infected; however, it is interesting to note that these dogs tend to a have longer 
survival times than animals that do not develop infections (32, 36). Similar observations have 




increased immune surveillance triggered by the acute infection may be suppressing metastatic 
growth leading to prolonged survival time.    
 
 Adjuvant chemotherapy must be administered following both amputation and limb 
sparing surgery to improve survival times (35). The primary reason for chemotherapy is to 
prevent or delay the development of distant metastases (35).  The most commonly used 
chemotherapeutics for bone sarcomas are cisplatin, carboplatin and doxorubicin (35, 38). 
Cisplatin is a heavy metal platinum compound that has been shown to have adverse effects on 
the renal system. Carboplatin is a second-generation platinum drug that has less severe effects on 
the kidneys and other organs. Doxorubicin is an anthracycline chemotherapeutic with the 
potential to cause dose related cardiomyopathy. These drugs damage cellular DNA and inhibit 
DNA repair mechanisms; therefore, interfering with cellular division and causing apoptosis of 
the cancerous cells (39).  The median survival time for dogs treated with amputation or limb 
salvage surgery followed by adjuvant single agent or combination chemotherapy is 
approximately 1 year (5). 
 
Despite increased survival observed with the addition of adjuvant chemotherapy over 
amputation alone; only about 50% of these dogs survive 12 months and 25% two years (20, 40). 
This relatively short time is due to OSA resistance to chemotherapeutics (20). However, there is 
evidence that activation of the immune system can kill chemoresistant cancer cells by activating 
tumoricidal macrophages and monocytes targeting the cancerous cells (41). Several immune 
modulators have been developed to help stimulate the immune system to attack the tumor.  One 




increase median survival in dogs with OSA from 77 to 222 days; thus, the use of these 
modulators may provide a therapeutic advantage in the future (42).  
 
Radiotherapy for Osteosarcoma 
 
Osteosarcoma has been reported to be relatively radioresisitant (43). Curative-intent 
fractionated XRT of OSA has been shown to be ineffective for long-term local tumor control 
unless very high doses of radiation are administered (43-45). At these higher total doses, the 
complication rate from acute and late radiation effects to normal tissue are unacceptably high. 
Because of this, curative-intent XRT of OSA has not been widely utilized in the curative-intent 
treatment of OSA. Total radiation dose delivered with XRT is limited by the radiation tolerance 
of adjacent normal tissues.  Human studies have found similar results using XRT for the 
treatment of OSA. Total doses of 30 Gy (1.5–3 Gy daily fractions) don’t result in tumor control 
of OSA, whereas higher total doses exceeding 55 Gy (1.5–3 daily Gy fractions) were successful 
(8, 46). Unfortunately, high doses have historically resulted in adverse effects to normal tissues 
and organs in the radiation field when fractionated XRT is used (43).   
 
In a study by Walters et al, 14 dogs diagnosed with OSA were treated with full course 
XRT and adjunct chemotherapy as a curative-intent therapy (47). Dogs received total radiation 
dosages between 48 and 59.6 Gy over approximately 19 fractions (2.9 Gy/Fx) delivered daily 
(Monday – Friday). Local tumor control was achieved in approximately 4 of 6 tumors analyzed 
(14 total) (47). It was also reported that the majority of dogs experienced acute radiation related 




survival when compared with palliative XRT. This study was limited by small number of cases, 
had varied sites of primary tumor location and lacked complete histological analyses after 
euthanization (47).  However, it demonstrates known limitations of utilizing finely fractionated 
XRT for curative intent treatment.  
 
Intraoperative irradiation therapy (IORT) is an alternative strategy that has been used to 
deliver a high biologically effective dose to the tumor while sparing normal tissues (14, 48). This 
technique involves a surgical procedure where the skin, tendons, muscles and nerves are 
retracted from the tumor-bearing bone. The patient is then treated with high doses of radiation in 
a single treatment in which normal tissues are refracted outside the treatment field.  In a study by 
Liptak, et al., thirteen dogs diagnosed with primary bone sarcoma underwent IORT with a single 
fraction of 70 Gy followed by chemotherapy. Local tumor control was achieved in 10 dogs while 
the remaining three experienced local tumor recurrence (48). Complications included pathologic 
fracture, which was observed in 7 dogs, and infection in 3 dogs (48).  The median survival of the 
animals was 298 days. In a separate study, five dogs with osteosarcoma (n=4) or anaplastic 
sarcoma (n=1) of the distal radius were treated with IORT with the aim of preservation of 
function of the radiocarpal joint. A single fraction of radiation between 45 and 100 Gy was 
delivered to the lesion (14). Chemotherapy was also locally delivered to the tumor site (14). The 
dog with anaplastic sarcoma experienced local tumor recurrence and was euthanized. One of the 
dogs with osteosarcoma experienced implant failure and the other three developed pathologic 
fracture. Survival, although in a small population dogs, was encouraging and ranged from 15 to 
24 months (14).  The use of IORT when combined with adjuvant chemotherapy, exhibits 




successfully used for the treatment of advanced pelvic, head and neck cancers in humans (49). 
This approach suggests that local tumor control and extended survival times may be achieved 
with high dose radiation therapy.  
 
Fractionated curative intent Radiation Therapy in Humans 
 
In humans, standard of care therapy for OSA involves limb-sparing surgery in 
combination with neoadjuvant chemotherapy (50). Amputation provides excellent tumor control; 
however, it is considered less ideal due to the resulting physical limitations. Limb sparing 
surgery may be associated with local tumor recurrence due to the inability to achieve wide 
margins during resection especially in difficult areas such as the pelvis and axial skeleton (46).  
Using radiation therapy alone has not traditionally been successful as it does not treat metastatic 
disease (51). A combination of chemotherapy and radiation, limb-sparing, pre-operative 
radiation therapy and chemotherapy have shown to be most effective (46, 52).   
 
In a study by Caceres, et al., 15 human patients were treated with radiation in 
combination with chemotherapy. Tumor control was observed in 80% of the patients compared 
with a previous study using radiation alone resulting in 20% tumor control (51, 53). However, 
pathological fracture frequently occurred and pulmonary metastases were present in 71% of the 
patients indicating the chemotherapy treatment was aiding in local tumor control but not for the 
prevention of metastatic disease (53). A limitation of this study was the lack of long-term follow-
up due to deaths from metastatic disease. The use of chemotherapeutics to prevent metastasis and 




tumor control at 5 years of approximately 56 percent (52). These patients were treated with 2.5 to 
3 Gy daily fractions for a median total dose of 60 Gy along with chemotherapy (52). In a similar 
study, the combined 5 year survival was 68 percent when patients were treated with a median 
dose of 66 Gy in 1.5 to 3 Gy daily treatments with chemotherapy (46). Interestingly, this study 
also included patients with previous gross or subtotal tumor resection which yielded a 78% 
median survival at 5 years (46). Other studies have shown that a combination of limb-sparing, 
chemotherapy and radiation therapy offers promise in the treatment of OSA.    Dincbas et al. 
showed that pre-operative radiation combined with chemotherapy showed a 5-year local tumor 
control rate of 97 percent and survival of 48 percent (50). The satisfactory local tumor control 
achieved with pre-operative radiation and limb sparing may be due to the further killing of OSA 
tumor cells at the resected margins which were not the previously removed due to narrow 
resection margins.  
 
Radiation Tissue Tolerance  
 
To better predict the radiation tolerance of tumors and normal tissues, a linear-quadratic 
model based on cell survival of many cell types (normal and cancerous) has been developed 





Figure 1: Late responding tissues have a lower alpha:beta ratio while most tumors and early responding tissues have a 
higher alpha:beta ratio (55). 
 
The alpha (linear) and beta (quadratic) ratio describes the curvature of the cellular survival curve 
in the model (54). Most tumors have a high a/b ratio (>7) and are considered to be radiosensitive 
to XRT (54).  Normal tissues such as kidney, skin, gastrointestinal tract and bone marrow 
undergo regular cellular proliferation and as such are also very sensitive to the effects of 
radiation. These tissues are known as acute responding tissues. However, normal tissues are 
better able to repair DNA damage between fractionated radiation doses compared to tumor tissue 
treated with XRT. Other normal tissues such as nervous tissue, lung, muscle and bone undergo 
cell division less frequently and are considered late-responding tissues. Tumors with a low 
alpha:beta ratio behave more like late responding tissues and are difficult to control with 
traditional fractionated radiation protocols. Fractionated radiation therapy can be successfully 
used to treat acute responding tumors (high a/b ratio) because the biologically effective dose to 




tumors (low alpha:beta ratio); however, a higher total dose of radiation or a high dose per 
fraction is needed to to obtain efficacy. Unfortunately, the high doses required to achieve tumor 
control results in unacceptable toxicity to the surrounding normal tissues when delivered via 
conventional XRT protocols. 
 
1.2 Stereotactic Radiation Therapy 
 
 Stereotactic radiotherapy (SRT) is a newer radiation treatment modality that precisely 
delivers high doses of radiation to well-defined tumor volumes with rapid dose fall off in 
surrounding normal tissues, thereby minimizing radiation exposure to these tissues. SRT has 
been successfully used for solid tumor ablation in tissues such as; lung, liver, brain, prostate, 
head, neck and spine. SRT has the unique ability to accurately deliver high dose per fraction 
radiation using image guidance, multiple radiation beams and intensity modulation directly to the 
isocenter of a tumor. This ability, along with the ability to sculpt dose centered geometrically 
around to tumor allows for the preferential sparing of normal tissue (56). Because adjacent 
normal tissue is protected by this steep dose gradient, it allows for a smaller normal tissue 
volume to be affected by the radiation thus a higher biologically effective radiation doses may be 
administered to the tumor. This strategy is advantageous for treating relatively radio-resistant 
tumors (low alpha:beta ratio). Reports have indicated that OSA is relatively radiosensitive with a 
mean alpha:beta ratio of 3.5 and suggests SRT may be an advantageous therapy (57). 
 
Stereotactic radiotherapy has been successfully used for local tumor control of primary 




Gy of conventional XRT dosages are needed to achieve local tumor control in metastatic 
vertebral tumors (59). These higher radiation dosages are feasible with XRT, but the fraction 
sizes must be smaller due to the close proximity to the spinal cord (58). Smaller fractions make it 
difficult to achieve tumor control of OSA with XRT in this setting. Stereotactic radiotherapy is 
better suited for locations such as the spine because it reduces the volume of normal tissue 
exposed to radiation.  In a recent study consisting of 24 patients, SRT was delivered in 3 daily 
fractions of of 30 Gy to patients with primary and metastatic vertebral tumors (58). Patients with 
primary tumors (n=7) exhibited significantly greater pain relief and survival (Range: 29-49 
months) at a 33-month follow-up compared to those who received XRT. The remaining seven 
patients with metastatic tumor reported decreased pain and a mean survival of 11 months 
compared to five months with traditionally delivered XRT.  Complications related to SRT were 
minimal and no incidence of radiation myelopathy was reported (58). These results suggest that 
SRT may have a role in the treatment of primary vertebral tumors and palliative treatment of 
metastatic disease.  
 
In the past several years, SRT has become a new treatment paradigm for non-surgical 
limb salvage of canine OSA. In a study by Farese, et al, 11 dogs that presented with OSA in the 
appendicular regions were treated with SRT. The radiation treatment protocol consisted of one 
large fraction of radiation (20-30 GY) with the intent to achieve local tumor control (60). 
Additionally, six of these animals were given carboplatin chemotherapy prior to SRT and then 
adjuvantly (60). Carboplatin acts as a radiosensitizer when given in combination with radiation 
therapy by enhancing single and double strand DNA breaks (27, 52, 61). It can also inhibit the 




tumors revealed decreases in tumor-associated swelling and calcification of the lesions at three 
months post SRT. Lameness decreased in all animals for up to three months post-treatment. At 
four months, dogs that were treated with SRT alone experienced pathologic fracture or tumor 
recurrence. Those that received chemotherapy combined with SRT had a median survival time 
greater than 365 days (n=6) (60). Similarly, we have observed excellent local tumor control in a 
prospective study with 50 dogs with appendicular OSA treated with SRT at Colorado State 
University. A Varian Trilogy linear accelerator with image guidance was used to deliver 3 
fractions of 12 Gy (36 Gy total) to the tumor lesion on consecutive days. Carboplatin was 
administered at the time of the first or second fraction of SRT and then continued every three 
weeks for a total of 6 treatments. Tumor control was assessed by percent tumor necrosis. The 
most common complication was pathological fracture, which occurred in 40% of dogs at a mean 
time of 5.8 months after SRT.  The median survival time for the dogs treated with this protocol 
was 275 days (Range: 66 to 723 days) (63). Taken together, these studies suggest that the 
combination of SRT and adjuvant chemotherapy is efficacious for tumor control in the treatment 
of appendicular canine OSA. However, pathologic fracture as a late-term complication continues 
to be a challenge.  
 
Normal Bone Healing and effects of Radiation on bone formation and healing 
 
 Normal bone remodeling involves a dynamic equilibrium in which osteoclasts and 
osteoblasts are continually renewing bone to achieve homeostasis with no net gain or loss of 
bone. In normal bone, osteoclasts resorb calcified bone and then osteoblasts induce new bone 




intramembranous and endochondral ossification. Intramembranous ossification is important for 
the development of flat bones such as the skull and clavicles. In these bones, bone is formed 
from mesenchymal progenitor cells that differentiate directly into bone forming osteoblasts (64, 
65). These osteoblasts secrete osteoid (bone matrix) and cells within this matrix become 
osteocytes (66). The accumulating osteoid with the formation of blood vessels and nerves 
become the trabeculae.  Finally, the external face of the matrix condenses to form the outer 
surface of the bone called the periosteum (66). Endochondral ossification is important for the 
development and growth of the long bones as well as for fracture healing (67). This process 
differs from intramembranous ossification. In this process, mesenchymal cells differentiate to 
form a collagen template (66). This template then recruits osteoblasts to form a primary site of 
ossification in the center of the diaphysis (64). Next, osteoblasts begin to produce osteoid to form 
the bone matrix and results in the formation of the bone collar around the shaft of the collagen 
templates. This matrix then begins calcification and results in the formation of cavities within the 
bone as well as two new centers of ossification in the epiphyses (66). Finally, ossification of the 
epiphyses occurs and cartilage remains in the growth plates and articular regions (66).  
 
 Fracture healing is a complex and highly regulated process that involves a cascade of 
biological events involving progenitor cells, osteoclasts, vascular and inflammatory cells as well 
as proinflammatory cytokines, growth factors and pro-osteogenic and angiogenic proteins. It has 
been described as a four stage process (68). A fracture results in disruption to the bone, marrow, 
and vasculature integrity. The first stage results in a response to the injury where macrophages, 
platelets and other inflammatory cells are recruited by the secretion of a plethora of cytokines 




factor, interleukin 6, etc.). These immune cells participate in the debridement of damaged cells 
and other debris. (68, 69).  The second stage involves the development of the soft callus. 
Mesenchymal progenitor cells migrate to the affected area and begin to differentiate into 
chondrocytes, forming a soft callus (cartilaginous matrix) that provides mechanical support as 
well as a template for new bone formation to occur (68). This callus grows to fill the void 
between the injury and normal bone. The chondrocytes then begin to mineralize the matrix by 
recruiting osteoblasts (68). Vascular endothelial cells also begin to infiltrate the matrix in this 
stage.  The third stage involves the formation of the hard callus and where primary bone is 
formed. The soft callus is slowly removed by osteoclasts and osteoblasts begin synthesizing the 
mineralized bone matrix (unremodeled) (68). The final stage consists of remodeling the 
immature hard callus into mature bone (Cortical/trabecular bone). This occurs through the 
dynamic process of remodeling with osteoblasts and osteoclasts which converts the woven bone 
into normal cortical bone (68).  
 
Radiotherapy has been shown to have detrimental effects on bone structure, remodeling 
and healing. It can decrease bone mineral density otherwise known as osteopenia. Studies have 
shown that irradiation with greater than 20 Gy can result in a 23% decrease in mineral density 
resulting in decreased bone strength and increasing the risk of fracture (70). Radiation also 
affects the nonmineralized bone components such as vasculature, marrow, osteoprogenitor cells, 
osteoclasts and bone forming osteoblasts (71). Whole body radiation doses as low as 10-12 Gy, a 
dose often used for the treatment of leukemia, will completely ablate the bone marrow (72). 
Bone forming osteoblasts and osteocytes as well as bone resorbing osteoclasts are also 




survive longer than osteoblasts post-radiation and continue to resorb bone and degrade the bone 
matrix (73). Uncoupling of the normal remodeling process can result in pathologic fracture, bone 
fragmentation, and impaired healing (73-75). Inflammation induced by irradiation can also be 
detrimental to bone healing by causing bone to release cytokines that attract immune cells that 
can destroy endothelial cells, induce thrombosis, and necrosis. In normal wound healing, the 
duration of cytokine release is relatively short; however, in radiation injury the inflammatory 
process can linger for much greater lengths of time. The length of the inflammatory processes 
after radiation has been shown to linger from 2 to 26 weeks depending on the total dose, fraction 
size and the time in which treatment was delivered (76). Larger fraction sizes over longer periods 
of time resulted in markedly increased production of inflammatory mediators (76). Clearly, 
radiation injury to bone involves many complex and detrimental processes affecting the bone 
structure, cellular components and recruitment of inflammatory cells that can inhibit the ability 
of bone to recover after radiotherapy. These effects persist longer with increasing dose and 
fractionation. Therefore, therapies designed to improve bone health following radiation injury 
must address these issues.  
 
 As previously discussed, the most common complication associated with SRT or any 
high dose radiation therapy of OSA-affected bone is pathologic fracture. This occurs due to pre-
existing tumor-associated osteolysis which causes biomechanical and structural weakening of the 
bone as well as the cytotoxic effects of radiation on the surrounding normal bone impairing the 
ability of bone to remodel and heal (14, 47, 60, 63). Pathologic fracture is a serious, limb 
threatening complication of SRT for the curative-intent treatment of OSA often resulting in limb 




New therapies that diminish the risk of fracture through radioprotection or bone 
regeneration strategies are needed in order to advance the use of SRT as a viable non-surgical 
limb salvage procedure for OSA. In humans, bisphosphonates such as pamidronate and 
zoledronic acid have been successfully used to decrease the frequency of fracture in osteoporosis 
and metastatic bone cancer by inducing apoptotic cell death of osteoclasts; therefore, inhibiting 
their ability to resorb bone a component of tumor associated osteolysis (79). The use of growth 
factors such as Transforming Growth Factor beta (TGF-b), have been used because of their 
ability to stimulate the proliferation and differentiation of osteoblasts (80). Ehrhart et al. showed 
that administration of TGF-b to rabbits after radiotherapy enhanced bone formation (81). Other 
important growth factors such as Basic fibroblast growth factor (bFGF) and Bone Morphogenetic 
Protein-2 (BMP-2) have also shown regenerative properties in irradiated bone (82). These 
growth factors administered alone, or in combination show promise for decreasing the risk of 
fracture in irradiated bone and are being investigated.  
 
The late effects of radiation therapy on bone and other tissues have been well 
documented and include secondary tumor induction, fibrosis, endocrine disorders and neural 
damage (83-85). These effects usually occur within 5 to 10 years after radiation treatment and 
can be irreversible or progressively more severe than that of short term effects (84). There is 
potential concern that SRT may induce similar late term effects due to the large dose per fraction 
radiation protocol used in late responding tissues such as bone, muscle and nerves. Currently, the 
long-term effects of SRT on bone are not well understood. Further studies are needed to better 




1.3 Mesenchymal Stem Cells 
  
 Mesenchymal stem cells (MSCs) are multipotent adult stem cells found primarily in the 
bone marrow, but have also been observed in other tissues including the liver, adipose tissue, 
lungs, placenta, blood and umbilical cord (87). MSCs have the potential to differentiate into 
various cell types including chondrocytes, adipocytes and osteocytes (88). Differentiation of 
MSCs is modulated by a variety of biological factors that are unique for each differentiation 
lineage. While the complex interactions that are required to promote differentiation are still being 
investigated, key pathways have been identified.  For example, in chondrogenesis, transforming 
growth factor (TGF-b), bone morphogenetic proteins (BMPs), growth differentiation factors 
(GDF) and Wnts (early mediators of differentiation) are critical for the differentiation of 
chondrocytes (87). Nuclear hormone receptor peroxisome proliferator-activated Receptor 
(PPARg) has been shown to be a potent regulator of adipogenesis (87).  In osteogenesis, BMPs, 
specifically BMP-2 and BMP-6, induce a gene called Runx2 which is a master osteogenic gene 
(87). Interestingly, various factors interact to promote a specific lineage. For example, Runx2 
can repress PPARg thus blocking adipogenesis and promoting osteogenesis. The converse is also 
possible where coregulators in combination with PPARg can block Runx2 to induce 
adipogenesis (87). The ability of MSCs to differentiate into many different cell types holds 
promising regenerative therapeutic potential. 
 
 Because MSC’s can differentiate into osteoblasts, the use of MSCs to help generate new 
bone is of particular relevance to this thesis. MSCs have been shown to promote bone new bone 




tissues, promote angiogenesis, regenerate bone, and accelerate healing (71, 89, 90). One mouse 
model consisted of an allograft implantation into diabetic mice that incorporated MSCs into the 
allograft (89). The presence of diabetes was hypothesized to additionally delay the bone repair 
process.  Briefly, a segment of the femur was removed and replaced with a demineralized bone 
matrix (DBM) allograft containing no cells or MSCs.  At just four weeks, significant increases 
(300%) in bone formation were observed in the mice with MSCs compared with the DBM alone. 
Furthermore, more mature bone was observed at 8 weeks in the MSC group (89).  A larger 
animal model using rabbits seeded MSC into the medullary canal and periosteal surface of 
allografts and compared healing to allografts without MSCs (91). Rabbits with MSCs exhibited 
significantly increased bone formation. Another important aspect of this experiment was the 
evaluation of allograft incorporation into the host bone. Poor allograft incorporation is the major 
cause of allograft failure (92). The results further indicated that MSCs enhanced allograft 
incorporation into the host bone at 12 weeks (91).  
 
 A fracture healing study investigated the healing potential of MSCs transplanted into 
fractured mouse tibias. (90). Tibias were stabilized with a stainless steel pin and then fractured 
using a bending device. MSCs were injected at the fracture site and evaluated at 7 and 14 weeks. 
Signifigant increases in bone callous and mature bone were observed in the MSC treated mice. 
Tibias were then subjected to biomechanical testing which revealed that MSC treatment 
increased stiffness and ultimate tensile strength (90). A rat model utilizing a femoral defect 
showed similar results; however, MSC’s in this study were infused through the left ventricle 
(93). Additionally, MSCs expressed the Green-fluorescent protein, which allowed for ex vivo 




increased bone healing as compared to the control group (no MSCs). Furthermore, fluorescent 
imaging showed MSCs were present at the site of the fracture which confirmed the ability of 
MSCs to home to the site of injury (93). These studies indicate that MSCs administered locally 
or systemically resulted in accelerated fracture healing when compared to animals that did not 
receive MSCs.  
 
 Mechanisms by which MSCs induce new bone growth have been proposed. They have 
been shown to directly induce bone formation by directly differentiating into osteoblasts 
(intramembranous ossification). Alternatively, they have been shown to form a collagen template 
first and then produce new bone via the endochondral pathway (94). Both localized delivery and 
systemic injection of MSCs have been effective in generating new bone (90). For systemic 
delivery, it has been shown that the inflammatory response (e.g. cytokines and chemokines) to 
bone injury creates a chemotactic gradient that allows administered MSCs to migrate to the site 
of injury (90). Additionally, MSCs can indirectly induce bone formation through osteoinduction.  
Osteoinduction is the process whereby cells can be stimulated to differentiate into bone forming 
osteoblasts (95).  This means that MSCs have the ability to secrete factors, such as stimulatory 
cytokines and growth factors, to nearby cells to induce growth (95). These factors then interact 
with host cells to induce cellular migration of osteoprogenitor cells, promote proliferation, 
modulate inflammatory responses and promote host angiogenesis (96).  Although the indirect 
actions by which MSCs stimulate other cells to produce bone are poorly understood, it is 
believed that these indirect actions may be as important if not more than the direct action in 





 Osteoinduction is often confused with osteoconduction, which is a material that possesses 
properties that allow bone to grow on its surface (95). Osteoconductive surfaces such as bone 
grafts or implanted biomaterials can serve as a scaffold conductive for bone formation. Examples 
of osteoconductive biomaterials can include pure titanium, hydroxyapatite, allografts and 
xenografts.  Some materials can be both osteoconductive and osteoinductive as they can be 
coated with growth factors (e.g. insulin-like growth factors, TGF-b, Fibroblast-growth Factor 
(FGF) and BMPs) and/or seeded with stem cells that can trigger bone formation in addition to 
serving as a scaffold. A few examples of these materials include demineralized bone matrix, 
autografts, and hydroxyapatite coated with growth factors or stem cells (98, 99).  
 
 Mesenchymal Stem Cells and Radiation 
 
Few studies have assessed the ability of MSCs to regenerate bone in irradiated areas, 
especially following high dose irradiation. Interestingly, a murine study suggests that MSCs can 
migrate directly to radiation-injured tissues (100). Another experiment showed that MSCs more 
readily migrate to irradiated tumors (101). Furthermore, MSCs have been shown to revitalize 
bone that has been previously irradiated (102). Together, these observations suggest MSCs may 
be targeted towards radiation-injured tissue such as bone and may subsequently result in bone 
generation or healing.  (100-102). Therefore, it is important to investigate the potential of MSC 
as a novel treatment for radiation induced bone injury since it is one of the leading complications 





The effects of radiation on the structural integrity and regeneration of bone has been 
extensively studied. Studies have shown the negative effects of radiation on bone mesenchymal 
stem cells (71). It is well known that the bone marrow and subsequently bone marrow MSCs are 
very sensitive to radiation therapy (103). This may help explain the decreased regenerative 
properties of irradiated bone. In a study by Cao, et al, the distal half of femurs in mice were 
subject to 4 Gy of ionizing radiation per day for 5 consecutive days while the proximal half were 
left untreated (71). Initially, all MSCs from the entire bone disappeared; however, MSCs 
repopulated in the proximal half while MSCs in the direct radiation field were absent. Free 
radicals induced by radiation have been shown to have detrimental effects to adjacent bone 
marrow MSCs (104). In the unirradiated half, free radicals increased directly after radiation but 
returned to basal levels at four weeks; however, in the untreated half, free radical levels remained 
high. The authors suggested that free radicals induced by radiation treatment caused a temporary 
dormancy of the MSCs in the non-irradiated half of the femur but the high levels remaining in 
the distal half led to MSC death. Histological analysis of the treated femurs also revealed 
decreases in the numbers of osteoclasts, osteoblasts and MSCs in the irradiated area compared to 
the unirradiated area (71). The authors proposed that destruction of the vasculature in the 
irradiated area most likely prevented migration of MSCs to the site of radiation injury. 
Decreasing radiation-mediated MSC death or introducing MSCs into these irradiated regions 








Mesenchymal Stem Cells and Tumor Promotion 
 
 Although MSCs have a number of promising therapeutic applications, there is also 
concern about their potential to promote oncogenesis (105). The ability to differentiate into 
multiple lineages poses the possibility that they may also mutate into cancerous cells or migrate 
to existing cancerous cells and promote abnormal growth and migration (105). A study by Hung 
et al showed intravenously injected MSCs migrated to existing tumor xenografts and resulted in 
increased tumor size compared with no MSC injection (105). In a subsequent osteosarcoma 
model, MSCs were also shown to migrate to the osteosarcoma tumor site and promote local 
tumor growth and metastasis (106). The tumor promoting properties of MSCs pose a potential 
risk for local tumor reoccurrence or acceleration of distant metastatic growth if used as therapy 
to regenerate bone. Given these observations, using MSCS for bone healing of primary OSA 
may promote the development of undetectable disease in the lungs or bone. 
 
1.4 Specific Aims 
 
Osteosarcoma is the most common form of primary bone cancer in dogs and humans.  
Curative-intent treatment options include amputation, stereotactic radiation therapy or surgical 
limb salvage for local tumor control with the use of adjuvant chemotherapeutics for the treatment 
of micrometastases. Stereotactic radiotherapy (SRT) is an emerging treatment modality for local 
tumor control of primary osteosarcomas due to its ability to deliver high dose per fraction 




with this treatment is pathologic fracture in the irradiated area due to pre-existing tumor 
associated osteolysis and loss of local remodeling capability of osteocytes secondary to SRT.    
 
Mesenchymal Stem Cells (MSCs) are multipotent stem cells that have the capability to 
differentiate into many cell types including bone.  The capability of MSCs to differentiate into 
bone suggests that they may have therapeutic benefit in sites of SRT treated bone thereby 
reducing the risk of pathological fracture. These observations, along with the clinical need for 
novel treatments for osteosarcoma, have led us to pose and explore the following hypothesis:   
 
Mesenchymal stem cells will promote new bone formation in osteosarcoma affected irradiated 
bone treated with ablative stereotactic radiotherapy  
 
This hypothesis will be evaluated by the following specific aims: 
 
Specific Aim 1: Developed an orthotopic rodent model of canine osteosarcoma. Completion 
of this aim will characterize an athymic rat model of a luciferase expressing osteosarcoma. This 
model will then be used in subsequent experiments to evaluate SRT as a treatment modality for 
OSA and the ability of MSCs to enhance bone regeneration post-SRT. Approach: We will 
characterize the growth and progression of canine osteosarcoma tumor cells injected into 
athymic rat tibias and femurs with serial radiography, bioluminescent luciferase imaging, micro-
computed tomography (microCT) and histological analysis. Additionally, a biomarker for bone 
resorption, pyridinium (PYD), will also be measured to correlate tumor-associated osteolysis 




We hypothesized that the canine OSA cell line would engraft and exhibit predictable temporal 
progression in the tibia and femur. We expected increased radiographic evidence and 
bioluminescence over time as well as increased PYD levels as a consequence of tumor 
progression. 
 
Specific Aim 2: Evaluated the effectiveness of SRT to achieve local tumor control in an 
orthotopic tumor model. This aim will test the hypothesis that SRT effectively achieved local 
tumor control in the orthotopic OSA rat model developed in Specific Aim 1. Approach: Athymic 
rats were inoculated with a canine OSA cell line in the distal femur and SRT was administered 
approximately two weeks later when engraftment was established. Different fractionation and 
total radiation dose protocols were evaluated. Local tumor control after SRT was monitored by 
serial in vivo radiography, luciferase imaging, urine PYD analysis and histology to evaluate the 
effectiveness of SRT to achieve local tumor control.  
 
We hypothesized that there would be a dose dependent increase in percent tumor necrosis. We 
further hypothesized that higher doses would be associated with higher necrosis (i.e. %TN > 
80%) and smaller doses would be associated with lower necrosis (i.e. %TN < 80%). We also 
expected the severity of any acute effects to be increased with an increased total dose. The 
results from this experiment determined the optimal fractionation and total radiation dose 
protocol needed to achieve desirable local tumor control and was used in Specific Aim 4. 
 
Specific Aim 3: Isolated Green Fluorescent Protein (GFP) expressing mesenchymal stem 




lineages.  This aim involved isolating bone marrow and adipose MSCs from transgenic rats that 
ubiquitously express GFP. Approach: MSC cell lines were established from bone and adipose 
tissues and GFP expression was confirmed by fluorescent imaging using a Xenogen camera. 
Additionally, isolated GFP-expressing MSCs were subject to three different lineage specific 
differentiation growth media to confirm their ability to differentiate into osteoblasts, 
chondrocytes and adipocytes.  
 
We hypothesized that MSCs isolated from the bone marrow and adipose tissue from rats would 
exhibit multipotency when subjected to differentiation media as well as GFP expression. These 
cells were used in subsequent experiments to evaluate the potential of MSCs to promote bone 
formation after SRT in the rodent model developed in Specific Aim 2. The GFP expression 
enabled the identification of the MSCs in histological analysis of the bone as well as 
differentiated between host and MSC mediated bone formation.  
 
Specific Aim 4: Evaluated the ability of allogenic MSCs to induce new bone growth after 
SRT. This aim tested the hypothesis that adipose MSCs could regenerate bone in SRT-treated 
bone. Approach: Rats were injected with canine OSA cells and treated with the optimal SRT 
protocol derived in Specific Aim 2. Two weeks after radiation, allogenic rat GFP expressing 
MSCs were injected either intravenously (IV) or intraosseously (IO) directly into the previous 
tumor-bearing site of the femur. New bone formation was determined using histology and the 
source of new bone formation (host or MSCs) by immunohistochemistry analyses. Animals were 
also monitored bi-weekly by radiography and luciferase imaging to determine if MSCs used for 




lesions. We hypothesized that MSCs would induce new bone growth in both the IV and IO 









The goal of these experiments was to develop and characterize an orthotopic model of 
canine OSA in a rat. This model could serve as a valuable tool to evaluate SRT as well as other 
adjunctive therapies. It allowed us to determine the appropriate timing of SRT intervention and 
optimization of SRT treatment protocols (dose and fractionation schemes) to achieve local tumor 
control that was developed in Chapter 3. Furthermore, it allowed us to investigate the potential 
therapeutic use of MSCs for bone generation after SRT in a tumor affected bone location as 
described in Chapter 5.  
 
Animal models of cancer have been developed to help characterize the disease and 
evaluate the efficacy of new therapeutic treatments. Allogeneic and xenogeneic tumor models 
have been used for studying the effects of new treatments. Xenogeneic models involve the use of 
cells from a species different from the host whereas allogenic models use cells from different 
individuals within the same species. Xenogeneic studies are often performed in immune-
compromised animals, so that tumors from different species can grow without rejection from the 
host. Despite this advantage, it is important to understand that immune-compromised recipients 
lack a normal immune response. This may alter response to treatment and therefore may not 
reflect the clinical scenario. Despite this limitation, xenogeneic models allow for the study of 
specific mechanistic questions and the evaluation of new treatments in large numbers of 





Orthotopic animal models of cancer have been shown to better simulate localized disease 
than heterotopic models, as they allow the tumor to grow in the typical anatomical site similar to 
the conditions in which spontaneous tumors occur. As a result, cancerous cells encounter a 
similar microenvironment to the spontaneously-occurring disease, wherein the cellular 
microenvironment more closely mimics the biologic and metastatic properties of the native 
cancers (107). In regards to these studies, the orthotopic model will better simulate the osteolytic 
processes such as lysis and destruction of the existing bone that are observed in clinical cases of 
OSA. Heterotopic locations do not expose the tumor to the same environment; therefore, they 
may behave in a manner less like that of spontaneously occurring disease in an orthotopic 
location. These locations are often used to simulate metastatic disease. Outcomes of 
experimental therapeutic interventions in these models may not translate accurately or reliably to 
the clinical setting.  As such, orthotopic models are considered superior as they more readily 
predict treatment outcome of spontaneous tumors when subjected to different therapies for 
localized treatment (107). 
 
Orthotopic mouse and rat models of primary osteosarcoma have been previously 
characterized (108-110). In a study by Nieves, et al, various canine osteosarcoma cell lines were 
injected into the tibias of athymic mice (108). OSA successfully developed and progressed in 50 
to 88 percent of mice depending on the particular cell lines.  An orthotopic rat model of rat 
osteosarcoma has also been recently developed that showed reliable and repeatable implantation 
and progression (109). To our knowledge, no orthotopic rat models of canine osteosarcoma have 





 The goal of specific aim 1 was to develop a reproducible, temporally predictable 
orthotopic rat model for canine OSA for the evaluation of SRT in Chapter 3. The rat was 
preferred over the mouse due to its larger relative size. It would not be feasible to administer 
SRT to a mouse due to the treatment field limitations of the linear accelerator. We hypothesized 
that an OSA intraosseously injected into the cancellous bone of the proximal tibias or distal 
femurs of nude rats would engraft and exhibit predictable temporal progression. The cell line 
used for these experiments was established from a spontaneous metastatic bone tumor in a dog. It 
was also transfected to express a bioluminescent luciferase reporter gene. When the luciferin 
enzyme interacts with the luciferase promoter on the luciferase gene of the OSA cell, photons are 
emitted and can be visualized through a bio-luminometer or specialized imaging equipment 
(111) This permits serial real-time in vivo visualization of the OSA cells throughout the 
experiment without the need to sacrifice additional animals. In addition, radiography, histology 
and microCT imaging techniques were also used to evaluate tumor engraftment, predictability of 
temporal progression and consequent production of osteolytic lesions.  
 
Osteosarcoma results in breakdown and release of Type I collagen due to tumor-
associated osteolysis. Bone tumors promote bone resorption by secreting growth factors and 
cytokines that stimulate osteoclastic bone resorption (112). The breakdown products of 
soteolysis  (NTx, PDY, and DPD) can be measured in the serum or urine by various commercial 
assays (113).   Serum and urine NTx levels can differentiate bone resorption associated with 
OSA compared to other orthopedic diseases such as osteoarthritis in dogs (114). In dogs with 
spontaneous OSA, NTx levels are elevated compared to healthy animals (114, 115). Treatment 
by amputation of the affected limb, administration of radiation and bisphosphonates in these 




Commercial assays for the detection of NTx do not exist for rats.  However, assays do exist for 
the measurement of PYD and DPD in rats. To evaluate the degree of tumor-associated osteolysis, 
we measured the levels of PYD in the urine and compared the mean PYD values between 
treatment groups.  
 
More than 90% of bone matrix is made up of Type I collagen which is cross-linked with 
deoxypyridinoline (DPD) and pyridinoline (PYD) providing support rigidity and strength (113).  
The breakdown of type I collagen by osteoclasts releases collagen fragments (NTx) and the 
pyridinoline cross-links (PYD and DPD (peptide bound or free)) from bone. These fragments are 
excreted in the urine. Peptide bound (Type I collagen fragment bound to PYD or DPD) assays 
include N-telopeptide ( NTx) which measures the N-terminus of the collagen fragment and N-
telopeptide (CTx) which measures the C-terminus of the collagen fragment (113). These are a 
direct measure of Type I collagen breakdown. Unbound PYD and DPD peptides are the end 
products of the metabolism of Type I collagen have also been shown to indirectly measure Type 
I collagen breakdown (113). These values have been shown to increase in rat models of 
metastatic bone cancer thus it should allow for the measurement of the osteolytic processes 















2.2 Materials and Methods 
 
2.2.1 Experimental Design: Two experiments were conducted to develop and characterize the 
animal model. See Appendix A for complete experimental details of experiments outlined 
in this Specific Aim. 
a. Twelve rats were inoculated transcortically with a canine OSA cell line into the 
proximal tibial metaphysis. Tumor engraftment and progression was documented 
with weekly radiography, bioluminescence imaging and urine PYD 
measurements.  Three randomly-selected rats were euthanized at 2, 3, 4 and 5 
weeks after OSA inoculation and the tibias were subject to microCT and histology 
analysis. 
b. Six rats were inoculated with OSA into the distal femur and followed for 6 weeks. 
The aim of this experiment was to increase the animal numbers to increase the 
statistical power of the data and to evaluate a different tumor cell inoculation site.  
Tumor engraftment and progression was documented with weekly radiography, 
bioluminescence imaging and urine PYD measurements.  All rats were euthanized 
6 weeks after tumor cell inoculation and the femurs subject to histological 
analysis. 
 
2.2.2 Cells: Abram’s luciferase-expressing canine osteosarcoma cell line was generously 
provided by the Colorado State University Animal Cancer Center.  Canine OSA cell 
validation was performed by multiplex PCR using mitochondrial DNA to ensure the cell 
line was from canine origin and free of contamination (117). The cells were grown at 
37oC with 5% CO2 in Minimum Essential Media (MEM) supplemented with 10% fetal 
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calf serum, 7.5% sodium bicarbonate, MEM essential amino acids, 10mM non-essential 
amino acids, L-glutamine and antibiotic-antimycotic. Cells were split approximately 
every 3 days (~90% confluency) by incubating in 0.25% Trypsin for 5 minutes, 
centrifugation at 1000g for 5 minutes followed by re-suspension and plating in growth 
media.  Luciferase activity was confirmed by exposing luciferase expressing OSA cells 
for 5 minutes to 75 ug/ml of expression was confirmed using a Xenogen IVIS 100 
(Caliper, Hopkinton, MA) at a 30 second exposure with medium binning. An example of 
the bioluminescence observed is depicted in Figure 2. 
Figure 2: Representative image of bioluminescence of the luciferase expressing OSA cells 
2.2.3 Animals: Immunocompromised athymic nude rats (RH-Foxn1rnu) were obtained from 
the National Institutes of Health and housed by Laboratory Animal Resources. All animal 
procedures were approved by the CSU IACUC Animal Protocol 10-1959A. A total of 20 
rats, six to eight weeks of age, were individually identified with ear tags. 
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2.2.4 Tumor Inoculation: Rats were injected with Abrams luciferase expressing canine 
osteosarcoma cell line into the proximal left tibia or distal left femur. For the tibia 
injections, a 22G hypodermic needle was inserted transcortically into the proximal 
metaphysis and 1x106 OSA cells in 50 ul of PBS were injected. In the femurs, a 22G 
needle was inserted into the femur at level of the trochantic fossa (Figure 3), advanced 
distally within the medullary canal with a rotating motion to the distal metaphysis and 
then withdrawn. A second needled attached to a 1cc syringe was then advanced to the 
distal metaphyseal region and 1 x 106 OSA cells in 50 ul of PBS were injected.  
Figure 3: OSA cell injection technique into the distal femur.   
2.2.5 Luciferase Imaging:  Rats were imaged weekly using a Xenogen IVIS 100 (Caliper, 
Hopkinton, MA). Five minutes prior to imaging, rats were anesthetized by chamber 
induction and maintained by mask (2-4% isofluorane with O2) and injected 
intraperitoneally with 150 mg/kg of luciferin (Caliper, Hopkinton, MA). Rats were 
positioned in left lateral recumbency in the Xenogen machine and images of the left tibia 
or femur were taken at 1 and 3 minute time intervals at medium binning. Quantitave 




(Caliper, Hopkinton, MA) by quantifying total photons/sec. The mean of the expression 
value (photons/sec) was recorded for each animal at each time point. The mean 
expression value for all animals were plotted to document the weekly change in 
luciferase expression.  
 
2.2.6 Radiography: Under inhalation anesthesia with isofluorane, digital radiographs of the 
tibias were acquired weekly following OSA cell injection using a MinXray TR90 X-Ray 
machine (Northbrook, Illinois) to document radiographic onset of tumor associated 
osteolysis and tumor progression. Rats were positioned in left lateral recumbancy with 
the affected leg down and the contralateral leg positioned away from the affected leg to 
obtain lateral and anterioposterior view radiographs of the affected tibia. Images were 
acquired with settings of 40kV, 3.72 mA at 0.14 seconds of all animals and stored 
electronically for comparison.    
 
2.2.7 Pyridinium (PYD) ELISA assay: Urine (~500 uL) was collected weekly starting 
immediately prior to tumor cell innoculationfrom the rats by manual expression, 
cystocentesis or catheterization while under anesthesia and stored in individually labeled 
Eppendorf tubes at -20oC until PYD analysis. The MicroVue Pyridinium cross-links kit 
(Quidel, San Diego, CA) was used to measure PYD in the urine. Samples were diluted 
1:20 in PBS and PYD levels measured by analysis per the manufacturer’s instructions. 
Urine creatinine levels were measured using the Cayman Chemical Creatinine Kit (Ann 
Arbor, MI) to correct for differences in urine creatinine concentration. The corrected 




the creatinine values. The data for each animal were recorded in a Microsoft Excel 
worksheet. Mean +/- standard deviation corrected PYD values were calculated for each 
treatment group and plotted at each time point. Statistical comparison of corrected mean 
PYD values was done between post inoculation time points and the baseline levels. 
 
2.2.8 Euthanasia: Three, randomly selected rats were euthanized at 2, 3, 4 and 5 weeks after 
OSA inoculation in the tibial inoculation experiment, so representative histology samples 
could be available at these timepoints. Eight rats were euthanized 6 weeks after OSA 
inoculation in the femur inoculation experiment. The rats were euthanized by deep 
general anesthesia (isoflurane by induction chamber and mask), followed by 
exsanguination by intracardiac aspiration and finally by cervical dislocation as a 
secondary means of ensuring euthanasia. The left hind legs of the rats were disarticulated 
at the coxofemoral joint. Soft tissues were removed and the legs were placed in 10% 
formalin. 
 
2.2.9 microCT:. The tibias were imaged by microCT analysis using a Scanco uCT40 
(Brüttisellen, Switzerland) at a 10-micron resolution in 10% formalin. Images were 
acquired of the entire length of the tumor bearing femurs to document loss of bone.  
 
2.2.10 Histology: Tibias or femurs were removed from formalin and decalcified in 10% formic 
acid for five days. Bones were sectioned (three 10um sections per sample) in the mid-
sagittal anterioposterior plane and stained with hematoxylin and eosin (H&E) by the CSU 




pathologist experienced with osteosarcoma (Dr. Barbara E. Powers).  The slides were 
examined and validated for the presence or absence of osteosarcoma. 
2.2.11 Statistics: Luciferase activity and PYD data were validated for normality using the 
Kolmogorov-Smirnov test.  If data was normally distributed, data were expressed as 
mean +/-SD and were evaluated for statistical significance using a repeated-measures 
ANOVA. Statistical significance for comparison of means of different groups was 
calculated using the pair-wise T-test using SPSS statistical analysis software. The 





Tumor lesions were observed in 10 out of 12 rats injected in the proximal tibia based on 
bioluminescence, radiobiology and histology resulting in an engraftment rate of 83 percent. 
 
Osteosarcoma cell injections. Insertion of the needle through the proximal tibial cortex was 
variable and difficult with this injection technique.  The needle would slide off the cortical 
surface due to the shape and density of the proximal tibia bone. In some animals, a limited open 
approach was used in an effort to visualize and penetrate the cortex.  This introduced additional 
anesthesia time and the possibility of surgical complications such as infection.  Since the 
transcortical hole created was perpendicular to the long axis of the bone, cells could escape into 
the surrounding soft tissues or could be seeded on needle exit. Soft tissue swelling of the 





Modification of the tumor cell injection technique in the second part of the experiment involved 
introducing the needle through the cortical bone of the proximal femur at the level of the 
trochanteric fossa and then into the distal metaphyseal region of the femur. This resulted in a 
more reliable inoculation technique.  The access point was remote to the tumor cell inoculation 
site; so extraosseous tumor development was not observed.  The procedure was very rapid, 
resulting in less morbidity for the animals.  This became our preferred method for tumor cell 
inoculation through the remainder of the studies with successful tumor engraftment in 8 out of 8 
rats (100%). 
 
Canine osteosarcoma cells successfully engraft and progress in the proximal tibia and distal 
femur metaphyses. 
 
Bioluminescence: Tumor cell viability was evaluated during the course of the experiment using 
bioluminescence imaging as shown in Figure 4. Relative luciferase expression levels were 
measured in all rats over the course of five weeks using the IVIS quantification software (Figure 
5). In the tibia model, luminescence intensity (an indirect measurement of tumor cell viability) of 
the OSA cells was relatively consistent with no differences over the first 4 weeks (Figure 4 & 5); 
however, by the 5th week no expression was detected (Figure 4 & 5). In the femur model, 
luciferase activity increased (Figure 4 & 5) and remained consistent with no significant 
differences until weeks 4 and 5 in which a significant 5-fold increase in luciferase expression 
was observed (p < .001). These results conclude that luciferase levels were unchanged in the 




points. The luciferase expression in the femur model; however, significantly increased by weeks 
4 and 5 indicating a more reliable indicator of disease progression. 
 
Radiography: The tumor-inoculated tibias and femurs of the rats were imaged weekly by digital 
radiography. Radiographic changes observed in the tibias consisted of a mixed lytic/proliferative 
change in the proximal tibia, which progressed in animals with successful tumor engraftment 
(10/12) over five weeks. Representative radiographs shown in Figure 6 A demonstrate the 
radiographic progression of the tumor lesion throughout the duration of the experiment. By the 
fifth week, the tumor involved the entire proximal half of the tibia and resulted in impairment of 
limb function (Figure 6A). In the femur model, tumor engraftment and progression was observed 
in all rats (6/6) as shown in Figure 6B. By the fifth week, pathologic fracture was observed in the 
majority of animals and the experiment was terminated. The observed radiographic changes and 
tumor progression were similar to those observed in spontaneous canine OSA cases.   
In both the tibia and femur model experiments, radiographic evidence of tumor was reliably 
evident by week 2 after tumor cell inoculation and observed radiographic changes at the week 2 
timepoint were similar to those seen at presentation in spontaneous osteosarcoma in dogs (Figure 
6).  No fractures had occurred in any animal at the week 2 time point; therefore, this timepoint 
was chosen to deliver SRT in the subsequent experiment. 
 
PYD levels increase after tumor inoculation in the femur model. To measure the degree of 
tumor-associated osteolysis, a PYD ELISA and urine creatinine was used to measure bone 
resorption. Urine samples were collected weekly in each animal. In the tibia model, there were 




model, corrected PYD levels were significantly increased over baseline (Week 0) levels 
throughout the duration of the experiment (p < 0.005) (Figure 7B).  
 
MicroCT confirms tumor associated bone destruction. To further confirm the progression of 
the OSA tumor and to document the degree of bone destruction, tibias and femurs were subject 
to microCT imaging.  As depicted in Figure 9, microCT shows a comparison of a normal tibia 
and femur and the OSA-affected tumor lesions at 5 weeks. There is evidence of bone loss and 
possible fracture due to tumor associated osteolysis in week 5.  
 
Histology: In the tibia model, histological analysis confirmed the presence of OSA in 10 out of 
the 12 rats. The femur model showed histological OSA in all distal femurs.  
 
Results Conclusion: The tumor engraftment rate was 83% in the tibia model and 100% in the 
femur model. Two weeks post OSA tumor inoculation was identified as the time point when 
tumors were detectable radiographically, exhibited elevated PYD activity and exhibited no signs 
pathological fracture.  The femur model was chosen because it exhibited the highest tumor 
egraftment rate, predictable luciferase activity and PYD levels. This time point was chosen as the 
best time for treatment interventions in subsequent experiments in Chapters 3 and 5 using this 









 The aim of this study was to develop an orthotopic rat model of canine osteosarcoma to 
determine the engraftment rate and temporal progression of tumor development in the proximal 
tibia and distal femur. Canine osteosarcomas lesions commonly develop in the metaphyseal 
regions of long bones of the appendicular skeleton such as the proximal humerus, distal radius, 
distal femur and proximal tibia (11). To our knowledge, there are no established orthotopic rat 
models of canine osteosarcoma, thus the development of this model provides a valuable 
translational tool to evaluate novel local treatments of OSA. Based upon the aforementioned 
results, the femur model was selected as the most appropriate to be used in subsequent 
experiments. This animal model will be used in Chapter 3 (Specific Aim 2) to evaluate the 
effects of SRT on normal and tumor-affected bone and in Chapter 5 (Specific Aim 4) to evaluate 
potential bone regeneration by MSCs after SRT.  
 
 We first injected canine OSA cells into the proximal tibia by inserting a needle through 
the tibial cortex and injecting the cells into the metaphyseal region. This technique has been 
previously used in mouse models of OSA; however, a rat proximal tibia is much larger and 
denser making needle insertion difficult (108).  We observed evidence of cell leakage into the 
muscular tissues resulting in an inadequate representation of the localized disease. We 
experienced a tumor engraftment rate in tibial injection rats of 83 percent, which is comparable 





 Due to the technical difficultly and variability experienced with injecting cells into the 
proximal tibia, we then injected the OSA cells into the distal femur via a distant access site for 
the second experiment. Slowly injecting the cells is critical to this technique as we observed in a 
pilot study that injecting cells quickly could result in an embolism and death. The femur injection 
technique was much easier to replicate and we believe it minimized the potential for 
extraosseous cell leakage after injection. Tumor progression was consistently observed with 
radiography and luciferase imaging. These findings were confirmed in all animals by histology. 
Engraftment rate in this model was 100 percent as compared to 83 percent in our tibia model.  
Similarly, a 100% engraftment rate was observed in a previous allogenic orthotopic rat model of 
rat OSA in which cells were injected into the distal femur (109). This technique allowed for 
growth of the OSA from the intramedullary tissue and eventual extension through the cortical 
bone from the endosteal surface, which is most representative of spontaneous tumor 
development.  
 
 To evaluate the tumor cell viability, canine OSA cells were previously transfected to 
express a luciferase reporter gene. This enabled us to track the cell viability in real-time 
throughout the duration of the experiment. We showed increasing luciferase expression (Weeks 
1-4) by the OSA in the tibia model suggesting the cells are viable and proliferating as the 
experiment progressed (10/12 animals). Interestingly, by week 5 the cells appear to lose their 
ability to express luciferase. In the femur model, we observed a consistent increase in luciferase 
expression in all animals until sacrifice at week 5. It is unclear as to why the tibia model lost 
luciferase expression at week 5; however, several factors may have contributed to this 




week time point for evaluation and may not be an accurate representation of the tumor 
progression in a larger population.  Next, histological analysis revealed viable OSA cells were 
present at week five despite the loss of luciferase expression; therefore, its possible the cells may 
have lost their ability to express luciferase (118). In addition to the viable cells observed, OSA 
has been shown to have a variable innate level of tumor necrosis with an average percent tumor 
necrosis level of 26.8 percent observed in this study. The large necrotic areas could have 
prevented the luciferin from reaching the luciferase transfected tumor cells due to lack of blood 
supply in these regions.  It is possible that the tumor cells were still viable and the lack of 
bioluminescence may be due to inability of the luciferin to physically connect and react with the 
luciferase containing tumor cells. It has also been shown that small decreases in oxygen levels 
can affect the ability of cells to express luciferase (118). Osteosarcoma has been traditionally 
been considered hypoxic due to large necrotic regions, thus, the lack of oxygen could have 
affected bioluminescence of the cells (118). Signal attenuation is also a potential inhibiting 
factor, due to the altered absorption of the light through mammalian tissues (119). It is estimated 
that the signal can be attenuated as much as 10 fold through each centimeter of tissue; therefore, 
it is possible that the bone and soft tissues could be decreasing or eliminating the signal (119). 
Although bioluminescence allows for real-time imaging in vivo, it requires a complex interaction 
of many molecules and may not provide a true representation of the biological processes present 
(118).  
 
 We also measured pyridinoline (PYD) levels in order to establish baseline values and 
compare PYD levels over time after OSA inoculation to this baseline value. Increases in PYD 




monitoring response to treatment (115, 120). Similarly, a rat model of metastatic bone cancer 
showed increased PYD levels associated with tumor progression (116). We needed to 
characterize PYD changes over time in this model to ascertain the influence of SRT on this 
parameter in later experiments. In the tibia model, we showed no differences between groups 
throughout the experiment. In the femur model, we observed significant increases in PYD levels 
two weeks after tumor inoculation. These increased PYD levels persisted throughout the duration 
of the experiment and indicate an ongoing osteolytic process induced by the tumor. It is unclear 
as to why PYD levels did not increase in the tibia model while increases were observed in the 
femur model. The data may have been confounded by the fact that we experienced difficulty 
obtaining urine, initially. We were unable to obtain adequate amounts of urine from each animal 
in the tibia studies for an accurate analysis. Our technique greatly improved in the femur model, 
which allowed for a more thorough analysis.  
 
 A major limitation of this aim is the limited number of animals in the tibial study.  The 
serial sacrifice required to obtain histologic specimens at each week greatly reduced the number 
of animals that could be used for the PYD analysis in the later weeks of the experiment. It may 
have yielded a higher engraftment rate as well if all 12 animals were alive at the five-week time 
point. Increasing the number of animals could help decrease the variability of the PYD data and 
possibly yield a higher tumor engraftment rate.  An additional group of animals of the same age, 









 In this study, we developed an orthotopic model of canine osteosarcoma in the proximal 
tibia and distal femur of athymic rats. This model exhibited similar radiologic and histologic 
characteristics to spontaneous OSA in dogs. We showed a predictable temporal progression of 
the tumor lesion with an 83% engraftment rate in the tibial and a 100% engraftment rate in the 
femur model.  Additionally, we showed that radiographic tumor progression is consistent with 
increased luciferase expression as well as breakdown of collagen by measurement of PYD levels. 
The increased bone resorption as supported by the increased PYD levels is commonly associated 
with OSA progression. This series of experiments described a novel orthotopic rat model of 
canine OSA that was used in subsequent experiments. This model may be advantageous in that it 
can be used to evaluate new therapies that cannot otherwise be performed in mice due to size 
constraints or in client-owned dogs due to ethical concerns.  
 
The experiment described in this Chapter has been accepted for publication in the American 






Figure 4: Representative bioluminescence imaging of the luciferase expressing OSA cells in the femur and tibial locations. 
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Figure 5: Relative Luciferase expression over 5 weeks in the tibia and femur models. In the tibia model, the number of 
animals per weeks is as follows: week 1 (n=12), Week 2 (n=12), week 3 (n=9), week 4 (n=6), and week 5 (n=3). There were 
not statistical differences between weeks. The femur group consisted of 6 animals per group at each time point. Levels 






















Figure 6: Representative radiographs of the tumor-inoculated proximal tibias (A) and distal femurs (B). Radiographs 
demonstrate the radiographic progression of the tumor lesion during the five weeks of the experiment.
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Figure 7: Weekly PYD levels over 5 weeks in the tibia and femur models. A) PYD levels are unchanged throughout the 5 
weeks of the tibia experiment. B) PYD levels significantly increase from baseline (Week 1) at Week 2 and remain 





















































Figure 9: MicroCT of the tumor lesion in the proximal tibia (Top) and distal femur (Bottom) compared to normal bones. 










Stereotactic radiotherapy is a novel treatment modality for local tumor control of OSA in 
canines. It has the ability to accurately deliver large dose per fraction radiation precisely to the 
tumor lesion with relative sparing of the adjacent normal tissues and organs (60, 63). Durable 
local tumor control has been observed in dogs with spontaneous OSA of the extremity treated by 
SRT and the radiation side effect toxicity profile is acceptable (60, 63). The most common post-
SRT complication observed after treatment of primary OSA in dogs has been pathologic fracture. 
This is caused by pre-existing tumor-associated osteolysis and the adverse effects of high dose 
radiation such as decreased bone mineral density and the destruction of vasculature, osteoblasts 
and osteoclasts. (60). The overall objective of this thesis involved exploring the use of 
mesenchymal stem cells as a novel technique for regenerating bone after SRT of a primary bone 
tumor. Before this objective was met, a study was required that evaluated the optimal dosing and 
fractionation parameters of SRT to achieve local tumor control while sparing adjacent normal 
tissues in the model developed in Specific Aim 1.  
 
Conventional finely fractionated radiotherapy (XRT) involves delivery of radiation in 
small dose fractions (typically 2-3Gy per fraction) to achieve a larger total radiation dose to the 
tumor yet permitting normal tissues to repair. This commonly used technique can result in better 
tumor control as well as decreased acute and late radiation effects because of the differences in 
radiosensitivity of the tumor and normal tissues and the ability of these tissues to repair damage. 




describe the benefits of using fractionated schemes for maximizing tumor control while 
minimizing acute effects of normal tissues (55). One-third of radiation induced DNA damage 
(direct damage) is caused by direct ionization and damage to the DNA molecules (55). The other 
two-thirds of DNA damage (indirect damage) is the result of the ionization of water (H20) to 
form highly reactive hydroxyl (OH) free radicals (55). A large single dose of radiation to a tumor 
can deplete the available oxygen for this reaction to occur thus limiting the formation of OH free 
radicals and decreasing efficacy. The depleted oxygen can also help the tumor cells to better 
repair DNA damage.  Thus, a large single dose decreases the effects of indirect damage and 
subsequently limits the total overall damage to the DNA (55). Radiation delivered in smaller 
fractions over a period of many days allows time for intra-tumoral pressure to decrease, opening 
blood vessels. Oxygen can then return to the tumor thus increasing the effectiveness of the 
radiation treatment via indirect action. The benefits of reoxygenation are particularly important 
for hypoxic tumors such as OSA. 
  
The relative radiation sensitivity of cells at different stages of the cell cycle is also 
important for fractionation. Cells are most sensitive to radiation in early S phase and G2/M phase 
of the cell cycle (55). Although it is possible to determine the current the proportion of cells 
within a particular phase of the cell cycle in vitro, it is not feasible in the clinical setting (121). 
However, fractionated radiation therapy provides a greater chance of treating during a radiation 
sensitive cell cycle relative to a single dose of radiation. This redistribution of cells to a 





Repair and regeneration are important benefits of fractionated radiation therapy for the 
protection of normal tissues. Normal cells repair themselves from radiation damage differently 
than tumor cells. Fractionation allows for repair of acute responding normal tissues from sub 
lethal radiation damage between fractions. The relative difference between normal acute 
responding tissues and more rapidly dividing tumor cells allows the therapeutic effect of 
radiation therapy to occur. The repopulation of undamaged cells, both normal and malignant, 
must also be taken into account in terms of time between fractions. An optimized fractionation 
and total dose protocol is developed based on the radiosensitivity of the specific tumor type as 
well as the normal tissues surrounding the tumor. 
 
Osteosarcoma has been traditionally referred to as “radio-resistant” due to the large total 
dose of radiation needed in order to achieve local tumor control. Conventional fractionated 
radiation therapy for local control of bone tumors has been generally unsuccessful due to the 
adverse effects on normal tissues because of the cumulative dose required for tumor control. 
Studies of human vertebral tumors required total doses exceeding 70 Gy (59). Similarly in 
canines, more than 90 Gy is needed for local control of osteosarcoma when given in several 
fractions (122). These higher total doses increase the rate for detrimental and permanent effects 
to the normal surrounding tissues including bone thus these large doses are not used clinically. 
Unlike conventional XRT which utilizes small doses of radiation over longer periods of time, 
SRT uses a larger dose in fewer fractions (56). Delivering a larger dose per fraction in fewer 
fractions has been shown to be advantageous in killing less radiosensitive tumors with a high 
alpha:beta ratio such as OSA (60). Although larger fractions can achieve better therapeutic 




conventional fractionated radiation therapy allows for a large dose to be administered to the 
tumor with a rapid dose fall off surrounding normal tissues. This is accomplished by using image 
guidance where radiation is precisely administered directly to the tumor while sparing 
surrounding normal tissues (56). The rapid fall off of radiation within short distances from the 
tumor also results in a smaller volume of normal tissue receiving the high and potentially 
deleterious dose. SRT also takes advantage of the reoxygenation, regeneration, repair and 
redistribution. Thus SRT allows for administering a higher biologically effective dose while 
sparing normal tissues, which cannot be accomplished with conventional fractionated radiation 
therapy. 
 
In this experiment, our aim was to determine the optimal SRT fractionation scheme and 
dose protocol to achieve local tumor control while sparing normal tissue in the orthotopic rat 
model of canine OSA developed in Specific Aim 1. First, we evaluated the feasibility of using 
SRT in small animals. We then investigated the ability to achieve local tumor control using three 
different fractionation protocols consisting of either one fraction of 25 Gy (total dose = 25Gy), 
two fractions of 15 Gy (total dose = 30Gy) or three fractions of 12 Gy (total dose = 36Gy).  For 
the two and three fraction protocols, each treatment was delivered on consecutive days. Acute 
radiation effects were monitored and compared between groups. Using the results from this 
experiment, we then assessed 4 different total radiation dose protocols of either 9 Gy (27 Gy 
total), 10 Gy (30 Gy total) , 11 Gy (33 Gy total)  and 12 Gy (36 Gy total), delivered in three 
fractions, and compared local tumor control and acute radiation effects in each group. We started 
with 3 fractions of 12 Gy because we have observed excellent tumor control with this protocol in 




an effort to minimize the acute and late radiation effects. We measured percent tumor necrosis as 
a measure of efficacy and additionally measured PYD levels to measure any decreases is 
osteolysis to the affected femurs. We hypothesized that percent tumor necrosis would increase as 
the total dose increased as well as decreases in PYD levels after SRT. We also expected the 
severity of any acute effects to increase as the total dose was increased. The protocol that 
resulted in the highest percent necrosis, while minimizing acute effects to normal tissue was used 
for the remaining studies.  
 
3.2 Materials and Methods 
 
3.2.1 Experimental Design: Two experiments were conducted to evaluate the effect of 
different fractionation schemes and different total dose (uniform fractionation) protocols. 
See Appendix B for complete experimental details outlined in this Specific Aim. 
1) Fractionation Experiment: This experiment compared delivery of SRT in one, 
two or three fractions. Three nude rats were inoculated (1 x 106 canine OSA cells) 
into the distal femur as described in Specific Aim 1. Two weeks after tumor cell 
injection, rats were administered SRT in the following fractionation schemes:  1 
fraction of 25 Gy (n=1), 2 fractions of 15 Gy (30 Gy total dose, n = 1) or 3 
fractions of 12 Gy (36 Gy total dose, n = 1). Local tumor control was assessed 
after SRT by serial radiography to monitor the progression of the lesion in 
comparison to OSA tumor progression documented in Specific Aim 1.  
Bioluminescence levels were used to assess tumor cell viability. Acute radiation 
side effects were monitored by digital photography of the treated leg and scored 
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using the VRTOG acute toxicity scoring system for skin. Rats were sacrificed six 
weeks after OSA cell injection or earlier if pathologic fracture occurred. The 
treated femurs were collected and analyzed to determine percent tumor necrosis 
of each sample. The experimental timeline is depicted in Figure 10. 
Figure 10: Fractionation experiment timeline 
2) Total Dose Experiment: This experiment was designed to assess different total 
radiation doses delivered with the same fractionation protocol.  Twenty-four nude 
rats were inoculated (1 x 106 canine OSA cells) into the distal femur as described 
in Specific Aim 1. Two weeks after tumor cell injection, SRT was administered in 
3 fractions delivered on consecutive days to the following groups: 9 Gy (27 Gy 
total, n = 6), 10 Gy (30 Gy total, n = 6), 11 Gy (33 Gy total, n = 6) or 12 Gy (36 
Gy total, n = 6). Local tumor control was assessed after SRT by weekly 
radiography to monitor the progression of the lesion in comparison to OSA tumor 
progression documented in Specific Aim 1. Bioluminescence levels were used to 



































to monitor changes in bone resorption after SRT. Acute radiation side effects 
were monitored by digital photography of the treated leg and scored using the 
VRTOG acute toxicity scoring system for skin. Rats were sacrificed eight weeks 
after OSA cell injection. If pathologic fracture occurred, the animals were 
euthanized immediately. The treated femurs were collected, stained with 
decalcified hematoxylin and eosin staining (H&E) and percent tumor necrosis was 
determined by a pathologist. The experimental timeline is depicted in Figure 10. 
Figure 11: Different total radiation dose, constant fractionation experiment timeline 
3.2.1 Stereotactic Radiotherapy Method: We previously determined that two weeks 
post-OSA inoculation was the optimal time for SRT administration based on our results from 
Specific Aim 1.  This time frame was sufficient to allow the tumor to engraft and progress 
such that it was detectable by radiography, bioluminescence imaging and increased PYD 





































Two weeks following tumor injections, rats were anesthetized as previously described in 
Specific Aim 1 and cone beam computed tomography (CBCT) imaging of the affected femur 
was performed for the purpose of radiation therapy planning. Animals were covered in bubble 
wrap to help maintain normothermia. Breathing was observed by closed circuit video 
monitors during each treatment episode. Non-invasive immobilization was achieved by 
positioning each rat in left dorsal recumbency (affected femur down) within an Accuform™ 
cushion indexed to the couch of the Varian Trilogy™ linear accelerator via a Civco™ 
baseplate (Figure 1). Transaxial computed tomography images of the affected femur were 
captured via onboard cone-beam computed tomography (CBCT). CBCT images were 
imported into the radiation therapy planning software (Varian Eclipse). Contouring of the CT 
images was performed on each tumor-bearing femurs, thus identifying the gross tumor 
volume (GTV), planned target volume (PTV), normal bone, and skin. The GTV consisted of 
contouring of the actual tumor itself and the PTV resulted from a 2 mm symmetrical 
expansion beyond the GTV. A SRT plan consisting of seven isocentrically placed treatment 
beams was created. A static multi-leaf collimator (MLC) was utilized to increase the 
conformality of dose achieved within the tumor volumes, while preferentially sparing 
surrounding normal tissues. Each plan was normalized to achieve a minimum of 99% of the 
desired dose within the GTV, and a minimum of 95% of the desired dose within the PTV 
based upon evaluation of the dose volume histogram (DVH). The total planning time for each 
subject was approximately two hours. In the fractionation experiment , rats were treated with 
either a single fraction of 25Gy; two, daily fractions of 15Gy; or three, daily fractions of 
12Gy. These animals were anesthetized during the entire planning stage and the delivery of 




consecutive days of either: 9 Gy (27 Gy total), 10 Gy (30 Gy total), 11 Gy (33 Gy total) or 12 
Gy (36 Gy total). These animals were anesthetized briefly for the CBCT acquisition, 
recovered and then anesthetized again the next day for the delivery of the first fraction. Prior 
to delivery of the second and third SRT fractions, rats were anesthetized and an orthogonal 
pair of kilovoltage radiographs of the femur were obtained with the Trilogy’s on-board 
imaging (OBI) system. These radiographs were matched to the digitally reconstructed 
radiographs derived from the original CBCT. Changes in couch position were made based 
upon the matching process to ensure precision and accuracy of SRT delivery.  Each field of 
the SRT plan was then delivered individually. Once SRT was completed, each rat was 
recovered from general anesthesia and returned to their cages.  Rats were then monitored 
weekly for response to therapy by radiography, bioluminescence imaging and PYD analysis. 
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Figure 12: Rat positioning in the bolus for SRT  
3.2.2 Imaging to document tumor progression and response to SRT: Luciferase and 
radiograph images were acquired once weekly starting before tumor inoculation for eight 
weeks as described in 2.2.5 and 2.2.6 to document tumor progression and response to SRT. 
3.2.3 Pyridinium (PYD) cross-links ELISA: Urine levels of pyridinoline cross-links 
(PYD), a marker of bone breakdown, were measured to document tumor associated osteolysis 
and response to SRT. Approximately 500ul of urine was obtained weekly from each rat for 
six weeks in the fractionation experiment and eight weeks in the total dose experiment as 




changes in PYD associated with SRT over time. Each urine sample was diluted 1:20 and 
analyzed in duplicate using the MicroVue kit per the manufacturers instructions.  Samples 
concentration was then corrected by dividing the PYD level by the creatinine levels in each 
sample. 
 
3.2.4 Evaluation of acute radiation skin effects: Following SRT, digital photographs 
for each treated leg were taken daily to evaluate acute radiation skin effects until the skin 
returned to normal pre-SRT appearance. The skin effects of SRT were then scored based on 
the Veterinary Radiation Therapy Oncology Group scoring system (Score 0 = No Change, 
Score 1 = mild, Score 2=moderate, Score 3 = severe) (123). The maximum grade skin effect 
and day of occurrence were recorded for each animal for comparison between treatment 
groups.  
 
3.2.5 Histology: Histological analysis was performed as described in 2.2.10. A single 
board certified pathologist evaluated percent tumor necrosis of all femurs. Tumor necrosis 
was calculated by dividing the necrotic tumor area by the sum of the total tumor area plus the 
necrotic tumor area (necrotic tumor area/(total tumor area + necrotic tumor area)) (124). 
Animals that exhibited no radiographic evidence of tumor or luciferase expression were 
omitted from the histology and PYD analysis because they would have skewed the data. 
Additionally, animals that exhibited radiographic evidence of tumor engraftment, but no 
luciferase expression at the end of the experiment were considered to have 95% tumor 




killed due to successful SRT.   
 
3.2.6 Statistics: Data in the PYD ELISA tests were logarithmically transformed and 
expressed as mean +/-SD.  Data were evaluated for statistically significant differences using a 
repeated measures ANOVA. Statistical significance for comparison of means of different 
groups was calculated using the pair-wise T-test. Mean percent tumor necrosis for each group 
is expressed as mean +/-SD and were evaluated for statistical significance using a one-way 
ANOVA. Statistical significance for comparison of means of each group was calculated using 
Tukey HSD and Bonferroni post-hoc analysis. The differences were considered significant at 





Stereotactic Radiotherapy results in high percent tumor necrosis of distal femur OSA. 
 
3.3.1 Fractionation Experiments 
 
1) Response to SRT: One fraction of 25 Gy SRT caused 99% tumor necrosis by 6 
weeks. Radiographs of the tumor lesion (n=1) showed progression and enlargement of 
the tumor along with increased bioluminescence at 1 and 2 weeks post tumor inoculation 
consistent with observations from Aim 1. One week after SRT treatment, luciferase 
imaging revealed a 60 % decrease in detectable bioluminescence suggesting SRT causes 
some tumor cell death ( Figure 14 & Figure 15). By 2, 3 and 4 weeks after SRT, no 
bioluminescence was observed and the lesions showed no progression indicated by no 
                                                




change in tumor size when compared to the femurs not treated with SRT at the same time 
points (weeks 2, 3 and 4) in Specific Aim 1 (Figure 13)., Interestingly, bioluminescence 
increased slightly at week 5 to 10% of baseline levels ( Figure 14 & Figure 15). 
Histological analysis indicated 99 percent tumor necrosis four weeks after treatment 
(Week 6) (Figure 16).   
 
2) Response to SRT: Two fractions of 15 Gy achieved 99% tumor necrosis by 6 weeks. 
Radiographs and bioluminescence showed engraftment and progression after OSA cell 
injection at weeks 1 and 2 (n=1). One week after SRT (week 3 post-tumor injection), 
luciferase imaging indicated a 57% decrease in detectable bioluminescence suggesting 
decreased tumor viability ( Figure 14 & Figure 15). By weeks 2 and 3 after SRT, no 
bioluminescence was observed and radiographs again indicated no tumor progression. 
Bioluminescence then increased 26% at week 4 and 57% at week 5 when compared to 
baseline ( Figure 14 &Figure 15). Histological analysis revealed a 99 percent tumor 
necrosis at week six (Figure 16).  
 
3) Response to SRT: Three fractions of 12 Gy SRT caused 80% necrosis at 6 weeks.   
As previously observed, tumor engraftment and progression was observed at weeks 1 and 
2 after OSA cell injection (n=1). One week after the third fraction of SRT, 
bioluminescence decreased 80% ( Figure 14 & Figure 15). As shown in  Figure 14, 
bioluminescence was undetectable throughout the remainder of the experiment and OSA 




80 percent was observed in the femurs in this treatment group at week six (Figure 16). 
 
Acute Radiation Effects 
 
Mild to moderate acute effects were observed after SRT in the fractionation 
experiment. Rats in each fractionation scheme were scored for radiation induced skin 
effects after SRT treatment each week until sacrifice at week six. Moderate acute effects 
were observed in the 1 x 25 Gy animal with a maximum effect at day 15 (VRTOG Score 
= 2, Table 1). In the 2 x 15 Gy and 3 x 15 Gy animals, effects were mild with a maximum 
effect at day 15 (VRTOG Score = 1) (Figure 16, Table 1). Skin recovered in all groups 
with noticeable healing and virtually no abnormalities by 18 days or for the rest of the 
experiment (Figure 16).  
 
3.3.2 Total Radiation Dose Study 
 
1. Tumor Engraftment: As shown in Figure 18, radiographs of the affected femur indicate the 
OSA tumor lesions engrafted and progressed as previously observed (Weeks 0-2). Mean 
PYD levels also increased before SRT treatment (Figure 20) 
 
2. Local Tumor Control: After SRT, serial radiographs (Weeks 2-8) of the tumor lesion 
showed no progression (Figure 18). Mean percent tumor necrosis at the end of the 
experiment in each group is as follows: 74% in 27 Gy (Range: 38-99%), 63% in 30 Gy 
(Range: 40-80%), 58% in 3 Gy (Range: 20-99%) and 87% in 36 Gy (Range: 80-99%) 




significance between treatment groups. No statistical differences in luciferase activity 
were observed in this experiment due to the high degree of variability in expression 
levels. However, there was an upward trend in expression after tumor implantation at 
weeks 1 and 2 (Figure 19) After SRT, luciferase activity decreased in a downward trend to 
negligible levels at 5 weeks (Figure 19). Spikes in luciferase activity were observed in 
limited numbers as follows 1 rat in 30 Gy (Week 6), 3 rats in 33 Gy (Week 6, n= 1, Week 
7, n =2) and 1 rat in 36 Gy (Week 7). There were no rats in the 27Gy group that showed 
recurrence of bioluminescence throughout the 8-week observation period.  
 
3. Stereotactic radiation therapy reduces PYD levels: No statistical differences between 
dosing groups were observed. In all treatment groups combined, mean PYD levels 
significantly increased by 2 Weeks post tumor injection from baseline (Week 0) (p < 
.0001) (Figure 20). After SRT treatment, levels significantly decreased 5 weeks (post-
injection) (p < 0.0001) suggesting that SRT is reducing normal bone resorption as well as 
tumor induced bone resorption by inhibiting tumor growth.  By weeks 6 and 7, PYD 
levels increased to baseline levels (p <0.004).  
 
Acute Radiation Effects  
 
Three daily fractions of 9, 10, 11 or 12 Gy per fraction cause mild acute effects to 
the skin.  
As previously observed with the fractionation study, mild skin lesions occurred 
predictably at a mean of 11 days (mean) after SRT treatment in all groups. As shown in 




increased; however, no animals were scored above a 1 for the VRTOG scale (Table 2). 
By 18 days, all animals showed little or no skin irritation, had healed and remained that 
way for the duration of the experiment. 
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3.4 Figures 
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Figure 16:Histology (H&E) of each femur at 6 weeks. Histological findings include areas of tumor necrosis, osteosclerosis 
and necrotic bone marrow.  
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Table 1: VRTOG radiation scoring for each fractionation protocol 
Organ/Tissue 0 1 2 3 













1 x 25 Gy   X  
2 x 15 Gy  X   
3 x 12 Gy  X   
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Figure 19: Relative luciferase expression in the total dose experimen
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Figure 20:  Mean PYD levels increased above baseline levels (week 0) at week 2 (p < 0.01 (A)) after tumor inoculation and 
then significantly decreased  as compared to Week 2 (C) after SRT treatment (Week 3, p < 0.0001). At week 5, PYD levels 
further decreased as compared to Weeks 2, 3, & 4 (C, D) (*p < 0.0001). PYD concentrations remained at these levels 
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Figure 21: Representative histology (H&E) in each total dose protocol at week eight. Histological findings include areas of 
tumor necrosis, osteosclerosis and necrotic bone marrow.
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Figure 22: Mean percent tumor necrosis in each dosing protocol with no differences were observed between groups. 
Large variability was observed between each group as follows: 3 x 9 Gy: (range 10-95%) 3 x 10 Gy: (range 40-95%) 3 x 

































































Table 2: VORTG scoring in each protocol 
Organ/Tissue 0 1 2 3 













3 x 9 Gy  X   
3 x 10 Gy  X   
3 x 11 Gy  X   



















3.5 Discussion  
 
Fractionated radiation therapy is commonly used for the palliative management of OSA 
in dogs in clinical cases. Previous studies have shown that administration of fractionated doses of 
ionizing radiation can help delay tumor progression and reduce pain (21, 27, 47). Studies using 
fractioned protocols such as 8-10 Gy fractions at 0, 7 and 21 days, 8-10 Gy at 0, 7, 21 or 28 days 
or 2 x 8 Gy on consecutive days showed a positive correlation in pain reduction (21, 27, 125).  
Although the side effects to normal tissue with palliative XRT were minimal, the total radiation 
dose and fraction scheme was not intended to achieve long-term local tumor control. Tumor 
recurrence and the associated clinical signs of pain and lameness occur again in the majority of 
cases. Another study evaluated curative-intent fractionated radiation therapy, dogs given total 
doses ranging between 48 and 60 Gy in 19 fractions showed local tumor control; however, the 
acute effects were excessive and thereby limited its clinical use (47). These studies showed that 
lower total doses exhibit fewer acute affects, but result in decreased tumor control. In contrast, 
studies using large doses per fraction with increased dose intensity over three days versus three 
weeks achieved better tumor control for tumors with low alpha:beta ratios such as OSA (47).  
The orthotopic model developed in Specific Aim 1 demonstrated a predictable tumor 
engraftment and progression of OSA that simulated the clinical setting. In this present study, we 
used this orthotopic rat model to evaluate the ability of SRT to achieve local tumor control with 









First, we conducted a pilot fractionation study that consisted of administering either one 
fraction of 25 Gy, two fractions of 15 Gy or three fractions of 12 Gy to the tumor-bearing femur. 
We evaluated the feasibility of administering SRT as well as the ability of these protocols to 
cause tumor necrosis and the potential acute radiation effects on normal tissues (skin) 
surrounding the tumor lesion.  
 
Previous studies evaluating radiation treatment of canine osteosarcoma have shown that a 
tumor necrosis of 80 percent or greater correlates with durable local tumor control and increased 
survival (124). In this study, we show that all three fractionation protocols result in 80 percent or 
greater tumor necrosis. Although all three protocols achieved desirable necrosis, the acute skin 
effects were markedly increased in the one and two fraction protocols. The three-fraction 
protocol achieved tumor control while minimalizing the acute skin effects. It is interesting to 
note the recurrence of luciferase expression in the one and two fraction protocols. This is 
difficult to explain because the mean percent tumor necrosis was higher in these groups than in 
the three-fraction protocol, which showed no recurrence of luciferase activity. Although 
luciferase activity has been shown to be a measure of in vivo cell viability, it requires a multitude 
of complex factors in order for adequate expression (118). Decreases in oxygen levels have been 
shown to decrease luciferase expression in vivo (126). These decreased oxygen levels have been 
observed in osteosarcomas, which are often found to be hypoxic (127). Additionally, the percent 




could be viable in other areas of the femur that were not observed by the pathologist. A major 
limitation of this pilot experiment was the small number of animals evaluated (n=3). Increasing 
animal numbers to at least eight per group would provide more statistical power to help better 
evaluate tumor control.  Even though preliminary, this experiment guided our choice of 
fractionation and doses for the remainder of the experiment. We concluded that SRT 
administered at 3 fractions of 12 Gy achieved acceptable tumor necrosis and minimized the 
adverse effects of radiation on normal tissue in this femoral rat model of OSA. We also 
determined that it was feasible to accurately position the rat for SRT treatment on consecutive 
days. This fractionation scheme has also been used in clinical cases of canine OSA. Furthermore, 
this experiment describes the first rat model of OSA using SRT that can serve as a basis of future 
experiments using SRT.  
 
Total Radiation Dose 
 
The results observed in the fractionation study suggest that a three-fraction treatment 
protocol was optimal to maximize tumor control and minimize acute radiation affects to normal 
tissue in this model. We then developed a dosing protocol to determine the minimal total dose 
needed to achieve tumor control using the three-fraction treatment regime.  In this study, we used 
total dose protocols of 27, 30, 33 or 36 Gy delivered in three fractions over consecutive days. We 
expected to achieve the best tumor necrosis with 3 fractions of 12 Gy. We also expected 




minimal as previously observed in the fractionation study; however, we expected to further 
minimize the effects with reductions in dose per fraction and total dose. 
 
Our results indicated that the mean percent tumor necrosis in all groups to be 
approximately 70 percent (Range: 10-95% ). Although we expected a difference in tumor 
necrosis between groups, no statistical significance differences were observed. Interestingly, the 
3 x 12 Gy total dose protocol resulted in the highest mean tumor necrosis of 87% (Range: 70-
95%) with the smallest variability. Tumor necrosis of 80% or higher after radiotherapy of OSA 
has been shown to be a valuable indicator of treatment response in both humans and dogs (124, 
128). Thus, we chose the 3 x 12 Gy protocol in subsequent experiments since it achieved the 
highest consistent tumor necrosis (>80%) when compared to the other protocols.  
To help compare our SRT protocol to that of previous studies, the concept of a 
biologically effective dose (BED) has been defined to more accurately describe the total dose 
delivered to as compared to conventional dose measurements (Equation 1).  
Equation 1: Equation for biologically effective dose where n=number of fractions, d=total dose. 
BED = n*d (1+ dα /β!" #$  
It takes into account the fraction size as well as the alpha:beta ratio of early and late responding 
tissues (55).   Our results indicate that the BED delivered in the 3 x 12 Gy SRT protocol, 
assuming a reported mean alpha:beta ratio of 3.5 Gy, was 159 Gy (57). Thus, this protocol 
administered a higher BED and resulted in higher tumor necrosis than that of previous studies in 




responsive and have a low alpha:beta ratio, radiation delivered in a larger dose per fraction 
yielding a higher BED appears to be more effective (127). This observation suggests that the 3 x 
12 Gy protocol may be directly applicable to clinical cases in canines and could result in better 
efficacy than that of traditional radiation protocols with low BEDs. The addition of 
chemotherapy along with conventional fractionated radiotherapy has also been shown to reduce 
the total radiation dose required for tumor control in OSA (124). Additional studies using our rat 
model of SRT in combination with chemotherapy may show that a reduction in total dose is 
possible whilst achieving the same or greater degree of tumor necrosis.   
 We also measured pyridinoline cross-links (PYD) levels to document the tumor-
associated bone resorption in response to SRT. We expected to observe decreases in PYD levels 
in the weeks following SRT treatment. We showed increased PYD levels at week two after 
tumor inoculation and significantly decreased levels after SRT treatment by week three in all 
groups. These decreased PYD levels suggest that SRT is inhibiting tumor associated bone 
resorption. Decreased PYD levels observed in this study along with increased tumor necrosis 
may serve as an indirect indicator of response to treatment. At week five PYD levels decreased 
further but increased slightly at weeks six and seven but remained below baseline levels. It is 
important to note PYD is a marker of global bone turnover; therefore, if PYD levels are not 
increasing it may indicate recurrence of OSA after SRT. Further studies are needed at longer 
time points to determine whether the increases observed at weeks six and seven continue in an 





 Finally, we monitored for skin effects with different total doses of SRT. As previously 
shown in our dosing study, minimal effects were observed in the 3 x 12 Gy treatment group. We 
expected to see similar acute effects as observed in the pilot experiment in the 3 x 12 Gy group. 
We then expected these effects to decrease as the total dose decreased. In this study, we observed 
similar effects in the 3 x 12 Gy group as in the pilot experiment. These effects decreased in 
severity as the total dose was reduced. The 3 x 12 Gy and 3 x 11 Gy group were similar while the 
3 x 10 Gy and 3 x 9 Gy groups showed little, if any, adverse effects. Moreover, none of the 
groups scored greater than a 1 on the VORTG radiation-scoring chart. Longer experiments are 
needed to evaluate the potential late-term affects of SRT especially on bone, muscle and 
peripheral nerves.  
Conclusion 
 The studies described herein evaluated the ability of different fractionation and total 
radiation dose SRT protocols to achieve tumor necrosis and minimize the acute radiation side 
effects to skin. In the preliminary fractionation study, all fractionation schemes achieved an 
average percent necrosis of greater than 80 percent.  It is important to note the limited number of 
animals of this pilot study make it difficult to make an accurate conclusion as to differences in 
tumor necrosis between groups.  Acute skin effects were higher in the 1 x 25 and 2 x 15 Gy on 
the VORTG scoring scheme than the 3 x 12 Gy group. The 3 x 12 Gy group had the lowest 
VORTG score with minimal acute effects. This led us to use this fractionation protocol to 
evaluate the minimum total dose using three fractions required to achieve tumor control.  In the 
total dose experiment, we observed a 70% mean tumor necrosis. Although, we did not see a 
difference between groups, the small standard deviation and higher average percent necrosis 




in the remaining experiments. These data are relevant as they show SRT delivered in 3 fractions 
of 12 Gy is capable of achieving greater than 80% necrosis. It also suggests that this model could 
be utilized to evaluate novel therapeutics for bone regeneration strategies after the use of SRT. 
This fractionation and total dose protocol (3 x 12 Gy) was chosen for the final experiment to 
evaluate the efficacy of mesenchymal stem cells to rescue irradiated bone after the treatment of 
















 Mesenchymal stem cells (MSC) are multipotent adult stem cells that have the potential to 
differentiate into various cell types, including chondrocytes, adipocytes and osteoblasts (88, 
129). The ability of these cells to differentiate into osteoblasts makes them an attractive 
candidate as a new therapeutic option for bone regeneration. In cell culture, MSCs will not 
spontaneously differentiate and need to be driven towards a specific lineage by certain culture 
conditions (e.g. growth factors) (130).  However, in vivo, the dynamic microenvironment in 
which the cells are exposed to have been shown to play an important role in their fate. MSCs 
exposed to an extra-cellular bone matrix tend to undergo an osteogenic commitment whereas 
MSCs exposed to cartilaginous tissue are likely to commit to chondrocytes (131, 132).  
 
Methods to distinguish MSCs from other cells such as hemacytoblasts and fibroblasts are 
controversial as there are no universally accepted methods (130).  Morphologically, MCSs 
exhibit plastic adherence as well as a swirling pattern of spindle-like and stellar shaped cells 
(133). One method of determining if plastic adherent cells are multipotent MSCs is to prove that 
they can differentiate into the three main MSC differentiation lineages (chondrocytes, adipocytes 
and osteocytes) (130, 134). This is accomplished by incubating MSCs with specific growth 
factors that can drive MSCs into different lineages thus aiding in identifying MSC 
characteristics. For osteogenic differentiation, the addition of dexamethasone to the growth 
media has shown to lead to osteoblast differentiation (130). Similarly for adipocytes, 




adipocytes. Finally, chondrogenic differentiation can be obtained by adding TGF-b to the growth 
media (130). These differentiated cells can then be visualized under a microscope using the 
following staining techniques. Alizarin staining binds to osteoblasts actively forming calcium 
and Oil Red O binds to lipid forming adipocytes (130). Chondrocyte differentiation can be 
confirmed by H & E staining and exhibits a distinct morphologic difference between 
undifferentiated MSCs and chondrocytes (130).  
 
 Flow cytometric analysis can also be used to differentiate various cell types by analyzing 
antigen expression patterns on the cellular surface. For example, hematopoietic cells have 
distinct and well-characterized antigen expression, which include CD34, CD38 and SCA-1 (130, 
135). Unfortunately for MSCs, many of the same antigens expressed on hematopoietic cells can 
also be expressed on MSCs. Furthermore, MSC antigen expression profiles vary greatly by 
experiment, laboratory and species. Many laboratories are attempting to identify a universal 
antigen expression profile of MSCs. Currently, some of the most commonly reported positive 
antigen patterns believed to be specific to MSCs are CD44, CD73, CD29, CD13, CD34, CD56, 
CD146, CD 106, CD 54, CD90, CD166 and CD105 (130). Negative antigen expression most 
commonly includes CD34, CD14, CD45, CD11b, CD49d, CD106, CD10 and CD31 (136). In 
some cases (CD34 and CD106) have both been shown to be negative and/or positive depending 
on the study. This is thought to occur because the antigen analysis of whole population of MSCs 
can include cells that may not be MSCs or that have already begun to differentiate into a specific 
lineage (adipose, osteoblast, etc.) (136, 137). Thus, there is no clear consensus as to a specific 





Although there does not appear to be a universally agreed upon antigen expression profile 
for MSCs, there are individual subpopulations of MSCs that can express specific markers. Some 
of these subpopulations have been associated with better differentiation down different lineages. 
For example, a recent report showed that subpopulations of MSCs could express a particular 
epitope of CD56 called 39D5. Cells positive for both CD56 and 39D5 exhibited greater 
differentiation potential towards chondrocytes. Cells expressing CD56 but lacking the 39D5 
epitope lacked the ability to differentiate into chondrocytes. The authors also noted a novel 
marker, MSCA-1, that when expressed resulted in better differentiation into adipocytes. 
Interestingly, when MSCA-1 was co-expressed with CD56, MSCs lost the ability to differentiate 
into adipocytes.  Another study reported that subsets of MSCs expressing CD105 are more 
capable of differentiating into chondrocytes (138). Thus, the isolation of subsets of MSCs with 
specific markers known to have better differentiation capabilities may have better regenerative 
properties than whole populations of MSCs. 
 
MSCs can be found in many locations throughout the body; however, the bone marrow 
and adipose tissue serve as easily accessible sources of MSCs (139). Both of these locations 
allow for collection through minimally invasive procedures. Bone marrow and adipose MSCs 
have been shown to differentiate down multiple lineages and have shown potential therapeutic 
efficacy (134, 140).  
 
In this study, we isolated bone marrow and adipose derived MSCs from transgenic rats 
that ubiquitously express Green Fluorescent Protein (GFP) by techniques previously described 




region. This promoter region has resulted in excellent expression of inserted genes in all tissues 
of the animal (144). Ubiquitous expression is of great value to these experiments because it 
enables all cells in the animal, including MSCs, to express GFP (143). It also allows for the 
progeny of cells isolated from these rats to also express the GFP protein. The ability of these 
MSCs to express GFP allows investigators to examine the fate of these cells after implantation 
into recipient animals by using histological analysis to determine their role in any new bone 
formation experiments conducted in Chapter 5 (143). The multipotent characteristics of MSCs 
isolated from adipose and bone marrow aspirates in GFP expressing rats were characterized by 
three-lineage differentiation. This was accomplished by administering osteogenic, adipogenic 
and chondrogenic factors to these cells, which have been shown to induce differentiation of 
MSCs into osteocytes, adipocytes and chondrocytes (130, 145). These experiments evaluated the 
isolation techniques by yielding cell cultures that exhibited morphologic characteristics similar to 
MSCs. Additionally, it assessed the ability of these cells to differentiate into the three main 
differentiation lineages to further confirm and characterize these cells as MSCs. We 
hypothesized that cells isolated from bone marrow and adipose tissue that exhibited plastic 
adherence and multipotency were indeed MSCs and would express GFP. These cells were used 
in Chapter 5 to evaluate whether exogenously administered MSC induce or directly cause new 












4.2 Materials and Methods 
 
See Appendix C for complete experimental details outlined in this Specific Aim 
 
 Mesenchymal Stem Cell Isolation 
 
 
4.2.1. Animals: Four Lewis 344-Tg rats ubiquitously expressing enhanced Green Fluorescent 
Protein (eGFP) were obtained from the Rat Resource and Research Center (Columbia, 
MO) and housed by Laboratory Animal Resources under approved IACUC Animal 
Protocol 11-2537A (143). These transgenic rats express the EGFP transgene under the 
control of the Ubiquitin C promoter region. 
 
4.2.2. Bone Marrow Derived MSC Isolation: Rats were anesthetized and then euthanized by 
cardiac puncture. Femurs (n=8) were harvested and placed in MSC growth media 
containing low glucose DMEM + 15% FBS. The distal and proximal ends of the femurs 
were removed exposing the medullar cavity (133). The cavity was then flushed with 
MSC growth media using 16, 18 and 20 gauge needles to disperse cells. Cells and media 
were collected into a conical tube and centrifuged for 5 minutes at 1000 RPM. 
Supernatant was removed and the cell pellet was re-suspended in MSC growth media 
and transferred to a 15 mL flask (133). The media was changed every three days until 
cells were 70% confluent and then maintained by sub culturing into additional flasks. To 
create frozen cell stocks, cells were trypsinized, washed with HBSS and frozen in 
freezing medium containing 10% DMSO, 44.5% FBS and 44.5% DMEM. 
 
4.2.3. Adipose Derived MSC Isolation: Subcutaneous and visceral fat were removed using a 




was then minced with a scalpel, placed in PBS and agitated for approximately 1 minute. 
An equal volume of collagenase was added to the adipose tissue cell suspension and 
placed at 37oC until the solution became homogenous (142).  Cells were then vortexed 
and then centrifuged at 1,200 RPM for 5 minutes. The supernatant was removed and the 
remaining cells were then placed in MSC growth media containing low glucose DMEM 
+ 15% FBS. The media was changed every three days until 70% confluency and then 
maintained by sub culturing into additional flasks.  Cells used in these experiments were 
in the third or fourth passage from initial isolation. Frozen cell stocks were made as 
previously described.  
 
Mesenchymal Stem Cell Characterization 
 
4.2.4. Osteogenic Differentiation: Rat bone and adipose derived MSCs were seeded 
separately onto 6 well plates at a density of 200,000 cells/mL and cultured as previously 
described until ~70-80% confluency. Osteogenic differentiation media was prepared as 
follows: Low glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented with 
10% FBS, 1mM dexamethasone, 01.M ascorbic acid, 1M glycerol-2-phosphate, 100X L-
glutamine and 100X antibiotic-antimycotic (130). Media was added to wells and 
replaced every three days for 21 days. A separate well with only growth media served as 
a control. Alizarin Red Calcium Stain was used to detect the presence of calcium after 
differentiation incubation period. Media was removed from plates and cells were fixed 
with ice cold 70% ethanol for 1 hour at room temperature. Cells were then rinsed twice 




added to cover the plate and incubated for 30 minutes (130). The plate was washed with 
PBS and then viewed under a microscope and stained osteocytes were visually observed 
and documented using digital photography under a microscope (4X magnification). 
 
4.2.5. Adipocyte Differentiation: Rat bone and adipose derived MSCs were seeded onto 6 
well plates at a density of 200,000 cells/mL and cultured as previously described until 
~70-80% confluency. Adipocyte differentiation media2 was obtained from GIBCO 
(Catalog #A10071-01) and supplemented with 50 ug/ul antibiotic-antimycotic. Media 
was added to wells and replaced every three days for 21 days (130). A separate well with 
only growth media served as a control.  Oil red-O staining was used to detect the 
presence of adipocytes after differentiation incubation period. Media was removed from 
plates and cells were fixed with ice cold 70% ethanol for 1 hour at room temperature. 
Cells were then rinsed twice for 10 minutes with PBS. Oil red O (Invitrogen, Carlsbad, 
CA) was then added to cover the plate and incubated for 30 minutes (130). Wells were 
then rinsed twice and visually observed and documented using digital photography under 
a microscope (4X magnification). Red coloration indicated that adipocyte cells were 
present. 
 
4.2.6. Chondrogenic Differentiation: Rat bone and adipose derived MSCs were harvested 
from 75 cm flasks and transferred to a 15 mL conical polypropylene tube at a density of 
approximately 100,000 cells in 500 ul of chondrogenic differentiation media. 
                                                





Chondrogenic differentiation media3 was obtained from GIBCO (Catalog #A10070-01) 
and supplemented with 50 ug/ul antibiotic-antimycotic. Cells were then centrifuged at 
450g for 10 minutes and incubated at 37oC with the caps loosened (130). Media was 
changed every three days for 21 days taking great care to not aspirate the pellet during 
media changes. A separate well with only growth media served as a control. At 21 days, 
the cell pellet had increased in size to approximatly1-2 mm. The chondrocyte pellet was 
carefully removed from the conical tube and placed in Histogel (Thermo Scientific, 
Waltham, MA). Cells were then sectioned into 5 um sections and placed onto glass 
slides. Slides were then stained with 1% toluidine blue/1% sodium borate for 5 minutes 
(130). The slides were then visually observed under a microscope for chondrocytes 
(positive for blue coloration) and digital photographs were acquired and recorded. 
 
4.2.7. GFP Imaging:  Cells were washed twice with PBS and then viewed under a 
fluorescence microscope with the GFP filter and a digital picture was acquired.  OSA of 














                                                







Rat bone marrow and adipose derived mesenchymal stem cells exhibit MSC-like 
morphology and growth characteristics. We were able to successfully isolate cells from the 
bone marrow and adipose tissue of rats that were consistent with MSC characteristics.  Both 
bone marrow and adipose derived MSC cell lines exhibited plastic adherence and visually 
resemble MSCs morphologically by exhibiting spindle-like and stellar shaped cells in an overall 
swirling pattern as previously described (Control group Figure 24) (133). Bone marrow derived 
cells grew significantly slower with a doubling time of approximately 3 to 4 days. Adipose 




Rat bone marrow and adipose derived mesenchymal stem cells differentiate into 
osteoblasts. Bone marrow and adipose derived mesenchymal stem cells were isolated from rats 
as described above. To confirm the potential of these cells to differentiate into bone, osteogenic 
factors (see 4.2.4) were added to the growth medium (differentiation medium) and evaluated for 
the presence of calcium by the Alizarin Red calcium-staining assay. After a 21day incubation 
period, no Alizarin Red staining was observed in cells incubated with normal growth medium 
(Figure 24A & C), which indicates no calcium was produced. In contrast, MSCs incubated with 
differentiation medium clearly show osteoblastic lineage as shown in Figure 24B & D indicated 
by the red staining. These results demonstrate and confirm the ability of the isolated rat MSCs to 






Rat bone marrow and adipose derived mesenchymal stem cells are capable of 
differentiating into adipocytes. To confirm the potential of these cells to differentiate into 
adipocytes, adipogenic factors were added to the growth medium (differentiation medium) and 
evaluated for the presence of fat globules by the Oil O Red staining assay. After the 21-day 
incubation period, no Oil O red staining was observed in cells incubated with normal growth 
medium (Figure 25A & C), which indicates cells were not differentiation into adipocytes. 
However, cells incubated with adipogenic differentiation medium clearly show adipogenic 
lineage as shown in Figure 25B & D indicated by the red staining of fat globules. These results 
demonstrate the ability of rat MSCs to differentiate into adipocytes. 
 
Rat bone and adipose derived mesenchymal stem cells are capable of differentiating into 
chondrocytes. To confirm the potential of these cells to differentiate into chondrocytes, 
chondrogenic factors were added to the growth medium (differentiation medium) and evaluated 
for the presence of chondrocytes by the Toluidine Blue staining after a 21-day incubation period. 
As shown in Figure 26, cells stained purple are indicative chondrocytes while cells stained blue 
are undifferentiated MSCs (130). These results demonstrate the ability of rat MSCs to 
differentiate into chondrocytes. 
 
 
Rat bone and adipose derived mesenchymal stem cells express GFP. GFP expressing bone 
marrow adipose derived mesenchymal stem cells were viewed under a fluorescent microscope 
(GFP Filter). As shown in  
 
 
Figure 27, both adipose (A) and bone marrow (B) derived MSCs expressed GFP. This confirms 
that the isolated MSCs express the green fluorescent protein. The control groups (C & D) did not 





The bone marrow adipose derived cells isolated from the GFP transgenic rats were determined to 
be multipotent mesenchymal stem cells based on characteristic morphology, plastic adherence 






















Figure 24: Adipose and bone marrow derived mesenchymal stem cell differentiation into osteoblasts as indicated by 
Alizarin red staining. A) Adipose derived MSCs incubated with control media and B) adipose derived MSCs incubated 
with osteogenic media. C) Bone marrow derived MSCs incubated with control media and D) bone marrow derived MSCs 















Figure 25: Adipose and bone marrow derived mesenchymal stem cell differentiation into adipocytes as indicated by oil 
red O staining. A) Adipose derived MSCs incubated with control media and B) adipose derived MSCs incubated with 
adipogenic media. C) Bone marrow derived MSCs incubated with control media and D) bone marrow derived MSCs 














Figure 26: Chondrogenic differentiation of MSCs. A) Adipose derived MSCs differentiated into chondrocytes. B) Bone 
marrow derived MSCs differentiated into chondrocytes. Purple staining is indicative of chondrocytes and the blue 




Figure 27: GFP expression in Adipose derived (A) and bone marrow derived (B) MSCs. GFP expression was not observed 










Mesenchymal stem cells have the ability to differentiate into osteoblasts, chondrocytes 
and adipocytes. The osteogenic potential of these cells offers new opportunities to develop 
therapies to regenerate bone in many different diseases. In this study, we evaluated the feasibility 
of isolating MSCs from bone marrow and adipose tissue from rats that ubiquitously express 
GFP. We also evaluated the ability of these cells to differentiate into osteoblasts, adipocytes and 
chondrocytes and confirmed GFP expression.   
 
Initially, we were able to successfully isolate cells purported to be MSCs from the bone 
marrow and adipose tissue of rats. Both MSC cell lines exhibited plastic adherence and visually 
resembled MSCs morphologically by exhibiting spindle-like and stellar shaped cells in an overall 
swirling pattern as previously described (133).  
 
Although these findings suggested that the cells isolated are MSCs, more confirmation is 
needed to further confirm the ability to differentiate into the three main lineages. Flow cytometry 
has been previously used in an attempt to identify cell specific markers for MSCs. These studies 
have been inconclusive as there is no consensus in the scientific community as to specific MSC 
markers. Additionally, the large number of anti-bodies needed is extremely costly and also 
requires a large number of cells (130). For the characterization studies described herein, we 
chose to characterize our MSCs by differentiating them into osteoblasts, adipocytes and 
chondrocytes, which has been described by several previous studies (130, 146, 147).  In this 
study, we exposed our isolated MSCs to specific differentiation factors for osteogenesic, 




differentiate into each of these cell types. These observations described herein suggest that the 
cells isolated from the bone marrow and adipose tissue are multipotent and meet the criteria of 
MSCs. Confirmation that the cells isolated in these rats are indeed MSCs is of particular 
importance because we intended to use these MSCs to regenerate irradiated bone in Chapter 5. 
Using cells that do not exhibit osteogenic potential would be detrimental to bone regeneration 
experiments.  
 
Both bone marrow and adipose derived MSCs were isolated in these experiments because 
they both have the potential to generate bone. Bone marrow MSCs; however, are scarcer, 
proliferate much slower and are more difficult to isolate than adipose MSCs (148). The 
abundance of adipose tissue in rats as well as in other animal models potentially makes adipose 
MSCs more ideal for tissue regeneration. Adipose MSCs are similar to bone marrow MSCs as 
they exhibit multipotent potential as well as similar phenotype and surface antigen expression 
(139, 149). It is thought that adipose MSCs are derived from bone MSCs that have circulated 
through the vascular system and deposited into the adipose tissue (149).  As with bone MSCs, 
adipose MSCs have also shown to aid in bone healing and regeneration. Adipose MSCs have 
been shown to repair bone in rat and rabbit critical defect models (150, 151). These MSCs can 
also recruit host osteoprogenitor factors and induce osteogenesis (148).  
 
A potential drawback of using MSCs to regenerate bone is that the difference between 
host induced and MSC induced osteogenesis cannot readily be distinguished. Our cells, as 
previously discussed, were isolated from rats that ubiquitously expressed GFP. We were 




formation versus MSC induced new bone formation through GFP histological analysis. New 
bone formed by implanted MSCs would express GFP while host cells would not express GFP. 
Additionally, using alizarin staining which binds to calcium, GFP expressing cells that stain 
positive for alizarin would indicate active bone formation from implanted MSCs. These 
histological techniques make it possible to distinguish between host and MSC mediated bone 
formation.  
 
 The data described herein show the successful isolation, differentiation and 
establishment of a MSC cell line from the bone marrow and adipose tissue from GFP expressing 
rats.   Differentiation into the three main lineages of the cells characterizes these cells as MSCs 
and confirms their potential to differentiate into bone in an animal model. Furthermore, GFP 
expression may aid in evaluating host and MSC mediated bone growth. Due to the abundance of 
adipose MSCs as well as their demonstrated osteogenic potential, we chose to use adipose 












Chapter 5: Evaluation of MSC mediated bone growth following SRT for the treatment of 
OSA 
 
5.1 Introduction   
 
 
 Mesenchymal stem cells (MSCs) are multipotent adult stem cells found in the bone 
marrow and adipose tissues. They are capable of differentiation into various cell types including 
osteoblasts, chondrocytes and adipocytes (88). The ability of MSC’s to differentiate into 
osteoblasts is of particular relevance to our studies as they could potentially generate new bone 
in osteosarcoma-affected bone irradiated with SRT. Several studies have shown that MSCs can 
home to damaged tissues, promote angiogenesis and regenerate bone (71, 89, 90). The 
observation that MSC’s migrate directly to radiation-injured bone suggests they could potentially 
be used to regenerate bone after irradiation. (100-102).  
 
  Although MSCs have a number of promising therapeutic applications, there is concern 
about their potential to promote tumor growth, especially when used as part of therapy in a 
cancer setting (105). They have been shown to migrate to existing tumors and there is concern 
that their presence may promote or accelerate tumor growth or metastasis (105). A recent study 
of OSA implanted into the proximal tibia of mice showed that systematically injected MSCs 
targeted local OSA, promoted growth of the existing tumors and resulted in pulmonary 
metastasis (152). Migration to the tumor by MSCs is likely mediated by various cytokines, 
chemokines and other growth factors secreted by tumors (152). MSCs also produce these same 




promoting properties of MSCs may pose a risk for local tumor recurrence or acceleration of 
distant metastatic growth if used as therapy to regenerate bone after irradiation of local OSA 
lesions. Thus, it is essential to examine the potential for tumor recurrence or progression when 
evaluating the therapeutic use of MSCs. Future studies are needed to evaluate safety, in addition 
to efficacy, before MSCs can be used in the clinical setting. 
 
The primary aim of these experiments was to determine if MSCs, administered by either 
the intraosseous (IO) or intravenous (IV) route, have efficacy in forming new bone within the 
irradiated site following SRT of osteosarcoma. Our secondary aim was to observe animals 
treated for signs of potential for local or distant tumor progression. We hypothesized that MSCs 
would induce new bone growth in both the IV and IO treatment groups and no new bone growth 
would be observed in the SRT only group.  
 
To test this hypothesis, we used the rat orthotopic canine OSA model developed in 
specific aim 1 and SRT treatment protocols as described in specific aims two and three. SRT was 
administered to the tumor-bearing limb two weeks after OSA cell inoculation using 3 x 12 Gy 
fractions delivered on consecutive days as previously described. Two weeks after the delivery of 
SRT, GFP-expressing MSCs were injected either intravenously through the tail vein (IV MSCs) 
or intraosseously into the left distal femur (IO MSCs).  Control animals had their OSA lesions 
treated with SRT alone but did not receive any MSCs (SRT Only). Based on the acceptable local 
tumor control (87% tumor necrosis and 5 of 6 rats with no recurrence of luciferase expression 6 
weeks after SRT) achieved using the 3 x 12 Gy SRT treatment protocol described in Chapter 3, 




Any local tumor recurrence observed would thus be due to the direct or indirect effect of the 
administered MSCs.  Serum Osteocalcin (OC) and urine PYD bone biomarker levels were 
measured throughout the experiment to monitor for evidence of bone generation and resorption 
respectively. Two days before sacrifice (Week 10), animals were injected with Alizarin red 
which binds to newly formed calcium in bone and has been shown to be indicative of new bone 
formation (154). After sacrifice, the femurs were imaged with microCT imaging to evaluate for 
differences in bone volume between treatment groups. A novel fluorescent histology technique 
was used to visualize and quantify alizarin staining, alkaline phosphatase for osteoblast activity 
and Tartrate resistant acid phosphatase (TRAP) staining for osteoclast activity and identification 
of any GFP expressing cells (155, 156). This novel technique involves overlaying each 
histological image (Alizarin, alkaline phosphatase and GFP) into one combined image that 
allows for distinction between host and donor mediated bone formation.  Non-decalcified 
hematoxylin histological staining was also used to document percentage tumor necrosis, new 
bone growth and possible tumor recurrence. 
  
5.2 Materials and Methods 
 
Experimental Design:  
Twenty-four rats were injected with 1 x 106 canine osteosarcoma cells into the left distal femur 
using the technique described in Specific Aim 1. Rats were randomly placed into one of three 
treatment groups (Table 1). All rats were treated with 3 x 12 Gy (36 Gy total) SRT two weeks 
after tumor cell inoculation. Two weeks after SRT, GFP-expressing adipose-derived MSCs 
(previously isolated as described in Chapter 4) were injected either intraosseously into the femur 
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(4 x 106 MSCs) (IO MSC Group, n=8) or intravenously into the tail vein (2 x 106 MSCs) (IV 
MSC Group, n=8). The remaining 8 rats received identical treatment but without MSCs (SRT 
only Group, n=8). Rats were followed after MSC injection by weekly radiography, 
bioluminescence imaging, PYD and osteocalcin markers for six weeks. Rats were sacrificed at 
week 10 and the femurs were subject to microCT imaging and fluorescent and histological 
analysis to determine total bone volume, GFP expression, osteoblast and osteoclast counts and 
percent tumor necrosis. See Appendix D for complete experimental details outlined in this 
Specific Aim. 
Table 3: Treatment Groups 
Treatment Group Description 
SRT only Group: (n=8) OSA + SRT 
IO MSC Group: (n=8) OSA + SRT + IO MSC  
IV MSC Group: (n=8) OSA + SRT + IV MSC  
 














































5.2.1 Tumor Cell Inoculation: One million (1 x 106) canine OSA cells were injected into 
the left distal femur of 24 rats using the luciferase-expressing Abram’s OSA cell line and 
inoculation technique as described in Chapter 2.2.4. 
 
5.2.2 SRT Treatment: Stereotactic radiotherapy was administered to all rats with 3 fractions 
of 12Gy (36Gy total) delivered on consecutive days.  The same animal positioning, CBCT 
imaging, radiation treatment planning and SRT delivery was used in this experiment as 
previously described in Chapter 3.2.1. 
 
5.2.3 Mesenchymal Stem Cell Injection: Two weeks after SRT, rats in the IO and IV 
groups (Table 1) were injected with the GFP-expressing adipose-derived MSCs that were 
isolated in Chapter 4. Rats were anesthetized to a surgical plane of anesthesia with isoflurane / 
oxygen by facemask.  The left hind limb was clipped of hair and scrubbed with 4% betadine 
and 70% ethanol. A cell suspension of 4 x 106 (IO MSC Group) or 2 x 106 (IV MSC Group) 
MSCs in a 10% heparin solution was injected over a period of two minutes into the distal left 
femur or tail vein respectively. Heparin was used to prevent a thromboembolism following IV 
injection that has been observed in previous studies in our laboratory. 
 
5.2.4 Imaging: Animals were monitored by weekly radiography and bioluminescence 
imaging of the left femur to assess tumor viability and radiographic changes using the same 






5.2.5 Osteocalcin ELISA: Osteocalcin (OC), a biomarker for bone formation, is a specific 
product of osteoblasts (157). It promotes the binding of osteocalcin to mineral and 
accumulates in the bone matrix. Osteocalcin levels in the bloodstream are considered to 
correlate with newly synthesized bone and have been shown to increase when using MSCs to 
induce bone growth (157). Osteocalcin was measured weekly from the serum. Approximately 
200 ul of blood was collected (Weeks 0, 2, 4, 5-9) under anesthesia from the tail vein and 
stored at -20oC. Sera was isolated from whole blood using BD Microtainer serum separation 
tubes (Franklin Lakes, NJ), diluted 1:10 and subject to the Rat Osteocalcin ELISA (USCN 
Life Science Inc, Wuhan, China) per the manufacturer’s instructions (ng/ml). 
 
5.2.6 Urine Collection and PYD ELISA: Urine was collected weekly (Weeks 0-10) and 
PYD and creatinine levels were measured by the ELISA assay as previously described in 
3.2.6.  
 
5.2.7 Euthanasia: The euthanasia protocol was modified in this specific aim to provide a 
more complete fixation of the rat femur that was required for the use of the novel fluorescent 
as described below. Two days prior to euthanasia, rats were injected intraperitioneally with 
30mg/kg Alizarin red to aid in identifying bone deposition in histological analysis. On the day 
of euthanasia, rats were then anesthetized under deep anesthesia by isoflurane. The animal 
was placed on the operating table with its back down and restrained. An incision with sharp 
scissors was made through the abdomen the length of the diaphragm to open up the thoracic 
cavity. While holding the heart steady with forceps, a 22G needle, attached to a perfusion 




scissors to allow blood and fluid egress during perfusion.  Approximately 200 mL of 0.9% 
saline solution was perfused through the animal via the ventricular needle perfusion pump at a 
flow rate of 20ml/min.   Once the blood cleared the body the saline solution was replaced with 
a 4% paraformaldehyde solution. Two hundred milliliters were perfused through the animal to 
ensure complete fixing of the tissues. The left femur was disarticulated at the coxofemoral and 
knee joints, the skin and partial soft tissues removed and the femur placed in 10% formalin.  
The femurs were imaged with microCT as described in 5.2.8. After microCT, the leg was then 
sent to Dr. David Rowe’s laboratory at the University of Connecticut for fluorescent histology 
and analysis. 
 
5.2.8 MicroCT: Femurs were subject to microCT analysis. Due to the variable location and 
size of the tumor in each femur, bone volume was normalized to three standardized volumes 
of interest within the tumor in each bone (Appendix D). Volume was calculated by averaging 
bone volume in these three sections each treatment group (IV and IO) and comparing them 
with the control group (SRT only) to evaluate any differences in bone volume that could be 
attributable to administered MSCs. Further details of this analysis is available in Appendix D. 
 
5.2.9 Histology: Femurs were sent to Dr. David Rowe’s laboratory at the University of 
Connecticut Health Center for cryosectioning and fluorescence imaging. This laboratory 
developed the novel fluorescent histology techniques used in these experiments (158). 
Untreated contralateral normal femurs (n=3) were used as a control standard for reference to 
compare against the SRT only, IO and IV MSC treatment groups. Femurs were sectioned at 




processed for sectioning. The samples were soaked overnight in 30% sucrose/PBS solution 
and embedded in Neg-50 frozen section medium (Richard-Allan Scientific, #6502).  
Longitudinal full-length 5 µm cryosections (Leica CM3050S Cryostat, Germany) of the femur 
were taken using a disposable steel blade (Fisher Scientific, # 3051835) and non-
autofluorescent adhesive film (Section Lab, Co., Ltd, Toyota-gun, Hiroshima, Japan 7250301) 
to capture the cut section.  Three sections, each selected from one of the three tissue depths, 
were chosen for microscopic examination.  They were transferred to a single glass slide (Gold 
Seal #3051) using a 2% chitosan (Sigma #C3646) solution in 0.25% acetic acid to adhere the 
film side to the glass surface and allowed to air dry for 48 hrs at 4ºC frost free refrigerator.  
Subsequently the four quadrants of the tissue slice were spotted with 1µl suspension of a 6µ 
fluorescent beads (Molecular Probes #I-14785m green; #I-14787 red) and allowed to dry for 
30 min.  The slide was soaked for 10 min in PBS, stained in a 30 mg/ml calcein blue solution 
(Sigma, #M1255-1G) for 30 min and cover slipped with 50% glycerin in PBS prior to 
microscopy for the endogenous fluorescent signals (bone mineral, mineralization lines and 
GFP when present).  
 
 Femur sections were transferred to a single glass slide (Gold Seal #3051) using a 2% 
chitosan (Sigma #C3646) solution in 0.25% acetic acid to adhere the film side to the glass 
surface and allowed to air dry for 48 hrs at 4ºC frost free refrigerator.  Subsequently the four 
quadrants of the tissue slice were spotted with 1µl suspension of a 6µ fluorescent beads 
(Molecular Probes #I-14785m green; #I-14787 red) and allowed to dry for 30 min.  The slide 
was soaked for 10 min in PBS, stained in a 30 mg/ml calcein blue solution (Sigma, #M1255-




endogenous fluorescent signals (bone mineral, mineralization lines and GFP when present).  
 
 After endogenous fluorescent signals were captured, the slide was removed from the 
microscope and the coverslip removed by brief soaking in PBS.  Osteoclasts were identified 
using the fluorescent ELF-97 phosphatase substrate (E6589, Invitrogen, (159)).  After 
imaging, the slides were process to identify cells expressing alkaline phosphatase (AP) 
activity using neutral AP staining conditions and the fluorescent substrate fast red (Sigma, 
#F8764-5G) (160).   Finally, hematoxylin staining was performed on the same slides after all 
the fluorescent staining and imaging steps were completed to generate a chromogenic image 
familiar to the bone biologist. 
 
 The fluorescent signals within the bone sections were recorded by a Zeiss Mirax Midi 
scanning fluorescence microscope (Carl Zeiss, Thornwood, NY) equipped with a 9 chamber 
filter cassette.  The bone mineral that was stained with calcein blue was detected with a DAPI 
filter (Chroma, #49000ET) while the AC mineralization lines utilized a TRITC filter (Chroma 
49005ET).  The osteoclasts that were stained with ELF-97 using a yellow filter optimized for 
tetracycline (Chroma Technology Custom HQ409sp, 425dcxr, HQ555/30, set lot C-104285), 
while the sections stained for AP activity with the fast red substrate used a TRITC filter 
(Chroma 49005ET).  This step does not conflict with the filter’s prior use to image the AC 
stain because the acidic condition of the TRAP protocol removes the fluorescent 
mineralization lines.  All of the fluorescent images were recorded with a high-resolution 
monochromic digital camera (Zeiss AxioCam HRm) and pseudocolored.  After all the 




Zeiss AxioCam MRc 5 color camera.  The Mirax software creates an image stack for each 
filter setting.  The stack of images for each staining set is merged as a flat file for a visual 
quality assessment before all files from each fluorescent imaging step are exported as a 
multilayered jpg file for image analysis. 
 
5.2.10 Statistics: Data in the PYD and OC ELISA tests were logarithmically transformed 
and expressed as mean +/-SD.  Difference between the mean PYD and OC values were 
evaluated between treatment groups at week 0, week 2 (SRT treatment), week 4 (MSC 
injection), week 8 and week12 (Sacrifice) using a repeated measures ANOVA. Statistical 
significance for comparison of means between time points was calculated using the pair-wise 
T-test. Mean tumor necrosis, microCT, bone volume and quantitative histological analysis for 
each group is expressed as mean +/-SD and were evaluated for statistical significance using a 
one-way ANOVA. Statistical significance for comparison of means of each group was 
calculated using Tukey HSD and Bonferroni post-hoc analysis. The differences were 





5.3.1 Tumor Development (Weeks 0-2): In all groups, the tumor lesions showed clear 
radiographic progression of the tumor at weeks 1 and 2 (Figure 29). Luciferase imaging was 




increases (p<0.05) in PYD over baseline levels were observed up to SRT treatment (Figure 30). 
Tumors development was observed in 100% of rats. 
 
5.3.2 Response to SRT (Weeks 2-4): After SRT, tumor lesions became stable radiographically 
in all groups as compared to untreated rats in Aim 1 (Figure 29). Luciferase levels were 
completely inhibited and PYD levels significantly decreased (p<0.05) after SRT to baseline 
levels (Figure 30).  
 
5.3.3 Response to MSCs (Weeks 4-12): Radiographic evidence of new bone formation in the 
IV or IO or SRT only groups was not observed throughout the duration of the experiment 
(Figure 29). Luciferase recurrence was observed in a limited number of animals at the end of the 
experiment as follows: SRT Only (n=1, 12.5%, Week 6), IO (n = 2, 25%, Week 5, 6) and IV (n 
= 3, 37.5%, Week 6, 7, 8). There were no differences in PYD levels between the IO and IV 
MSC groups and the SRT only control group after MSC injections at week 4 or at the end of the 
experiment (Figure 30, p < 0.19).  Osteocalcin levels in the IO and IV groups remained 
consistent with the SRT only animals after MSC injections. No differences in osteocalcin levels 
were observed throughout the experiment overall or between groups, even after MSC injection 
at week 4 (Figure 31). Osteocalcin values averaged approximately 14 ng/mL, which is 









Alkaline Phosphatase is decreased in rats treated with SRT. Alkaline Phosphatase (AP) is a 
marker of osteoblast-mediated bone formation. In Figure 34, AP is indicated by red staining and 
cell nuclei are indicated by the blue staining (DAPI) in the histological section of each group. 
Staining reveals decreased AP expression in the SRT only, IV and IO groups compared to the 
control femur and indicates limited or no osteoblast activity bone growth in these groups. 
Quantitave image analysis (Figure 38& Table 4) further indicates approximately 50-fold 
decrease in AP activity in all SRT treated groups compared with the control femur. 
 
Calcium formation is decreased in rats treated with SRT. Alizarin staining has been widely 
used as a marker of new bone formation as it stains calcium. In this study, rats were injected 
with alizarin two days before sacrifice. Using a fluorescent microscope, alizarin staining was 
visualized by the red color as shown in Figure 35. Levels in each treatment group are greatly 
decreased as compared to the normal bone indicating there is no new calcium formation 
present in these animals. Quantitave image analysis (Figure 38 & Table 4) further indicates a 
five-fold decrease in Alizarin activity in all SRT treated groups compared with the control 
femur. 
 
GFP imaging in rat femurs:  GFP expressing MSCs were injected IV or IO at week 4 into the 
distal femur of these rats. GFP expression in harvested tissues at sacrifice were evaluated to 
identify donor MSCs as well as any direct MSC mediated bone formation in the femurs. As 




compared to the SRT only group. These results indicate that there were no viable GFP MSCs 
present in the femurs or they had lost their ability to express GFP. 
 
Osteoclast activity is decreased in rats treated with SRT. TRAP staining is used as a marker 
of osteoclast activity (161). Using a fluorescent microscope, TRAP staining was visualized as 
shown in Figure 36. Osteoclast activity was decreased in all SRT treated groups as compared to 
the normal bone indicating there is little or no active bone resorption present. Quantitave image 
analysis (Figure 38& Table 4) further indicates approximately 50-fold decrease in TRAP activity 
in all SRT treated groups compared with the control femur. 
 
Percent tumor necrosis. Mean percent tumor necrosis at the end of the experiment in each 
group was as follows in each group: 96% SRT Only, 82% IO and 50% IV (Figure 33). The 
mean overall percent tumor necrosis was 76% (Range: SRT only, 90-99%, IO, 55-99% IV, 10-
95%). There was a significant increase in percent tumor necrosis in the SRT only group (95%) 
compared to the IV group (50%) (p < 0.040). Histology revealed large areas of necrosis and 
sclerosis indicated by areas of cells lacking nuclei (Figure 37).  Areas indicative of viable tumor 
consist of areas of randomly oriented confluent nuclei, which are consistent with osteoid 
development. Although viable tumor was found, they do not appear to be progressing in size. 
This is likely due to radiation damage that did not necessarily kill the cells but prevented them 
from replicating.  
 
Micro CT reveals no increase in bone volume between groups: After sacrifice at week 10 




volume between groups. Bone volume was normalized by selecting three equal regions of 
interest around the tumor and calculating the mean bone volume within those regions. Detailed 
methods describing the normalization can be found in Appendix D. As shown in Figure 32, no 
differences in volume were observed between the SRT only, IO and IV groups. These results 
indicate there was no increase in bone volume following the administration of IV or IO MSCs. 
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5.4 Figures 






































Figure 30: Mean PYD levels between groups. Data was log transformed to allow for easy interpretation. PYD levels 
significantly increased (p<0.05) after tumor induction (Weeks 1 & 2) and then significantly decreased within 1 week after 
SRT administration (Week 3) (p<0.05) and remained at these levels for the duration of the experiment (Weeks 4-8). 
Injection of MSCs showed no increase in PYD levels throughout the remainder of the experiment. 
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Figure 31: Osteocalcin levels between groups. There were no statistical differences between groups even after MSC 
injection
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Figure 32: Normalized bone volume between groups as measured by microCT. No differences in bone volume were 





















Figure 33: Percent tumor necrosis between groups. The IV group has significantly less tumor necrosis than the SRT only 












Figure 34: Fluorescent staining of cell nuclei, AP and GFP of histological sections in each group. Cell nuclei are indicated 
by blue (DAPI Staining), AK by red and GFP by green coloring. AK expression is decreased in all SRT treated groups 
indicating there are no active osteoblasts even after MSC implantation. Furthermore, no GFP expression is observed 

















Figure 35: Representative alizarin staining of histological sections in each group. The red coloring indicates the presence 
of alizarin or calcium formation. Alizarin expression is greatly decreased in the treated animals when compared to the 

















Figure 36: Representative fluorescent TRAP staining of osteoclasts in each group. Yellow coloring indicates viable 
osteoclast activity. Visually, only small amounts of TRAP expression is observed in any of the SRT treated groups as 


















Figure 37: Representative histological (Hematoxylin staining) of each group to document percent tumor necrosis. 















Figure 38: Percent expression of Alizarin, TRAP and Alkaline Phosphatase (AP) in the tumor area. No differences 
between the IV, IO and SRT only groups were observed. 
Table 4: Percent expression of Alizarin, TRAP and Alkaline Phosphatase (AP) in the tumor area. 
Group Alizarin % TRAP % Alkaline 
Phosphatase % 
SRT Only 4.89±3.29 0.12 ± 0.16 1.13 ± 0.28 
IV 6.04±4.16 0.21 ± 0.11 0.17 ± 0.18 
IO 3.92±3.80 0.07 ± 0.07 0.21 ± 0.28 


































 Mesenchymal stem cells are multipotent adult stem that have been shown to home to 
damaged tissues, promote angiogenesis and regenerate bone (71, 89, 90).  The ability of MSCs to 
promote these regenerative capabilities indicates that they may be useful in a variety of tissue 
engineering and regenerative therapies.  In relevance to this thesis, studies have shown MSC’s 
can migrate directly to radiation-injured bone and can promote osteogenesis (100-102). Although 
these studies show MSCs can migrate to injured bone and increase markers of bone formation, 
there are currently no in vivo studies assessing MSC bone generation after the use of SRT for the 
treatment of OSA.  In this present study, we used SRT to ablate OSA in the orthotopic rat model 
previously described herein and evaluated the ability of allogeneic adipose derived MSCs to 
regenerate bone after SRT.  
 
 Currently, studies assessing the use of MSCs for tissue recovery after radiation are 
limited and utilize low doses of radiation to non-tumor bearing animals.  One such study in mice 
consisted of administering total body irradiation (3.5 Gy total) and then intravenously injecting 
MSCs 24 hours after treatment. Animals treated with radiation had a high homing rate of MSCs 
to the bone marrow and muscle. Untreated animals showed little or no MSC engraftment to these 
tissues. This study suggests the potential of systemically injected MSCs to migrate to radiation-
injured tissues (162). In another study using a femoral defect model, rat allografts received a 
single radiation dose of 60 Gy, treated with MSCs and transplanted back into the heterotopic 
location (102). Femur segments receiving MSCs showed increased alkaline phosphatase and 
osteocalcin activity compared to control femurs indicating the possibility that MSCs can rescue 




 In our model, we injected GFP expressing MSCs intraosseously (IO) into the medullary 
canal of the tumor-bearing limb or intravenously (IV) into the tail vein two weeks after SRT. We 
hypothesized that the IO MSCs would directly engraft in the femur while the IV MSCs would 
migrate to the femur and result in increased bone growth.  Injecting MSCs immediately after 
SRT could potentially lead to tumor promotion, as the tumor cells may still viable. We sacrificed 
the animals six weeks after MSC implantation to allow for adequate time for MSC engraftment 
and new bone generation.  Unlike models previously discussed which showed increased markers 
of bone formation after irradiation, we showed no increases in osteocalcin or alkaline 
phosphatase in either the IO or IV MSC treated groups. Other studies showed homing of MSCs 
to the irradiated bone; however, our MSCs failed to show engraftment via GFP histological 
analysis. We also measured bone volume with microCT, PYD and osteoclasts levels (TRAP 
staining), which indicated no increases in bone volume or bone resorption after MSC injection.  
  
 It is well recognized that radiation can cause detrimental alterations not only to the 
physical bone properties, but also to the osteogenic progenitor cells, blood vessels and 
inflammatory responses, which are critical for normal bone growth and repair as well as MSC 
homing and engraftment (71, 81). Previous rodent models demonstrating the homing and 
osteogenic potential of MSCs after radiation are limited to low dose treatments (between 1 and 5 
Gy) (100, 162). In our model, we administered a much larger dose of 3 fractions of 12 Gy  (BED 
= 159 Gy). The large dose in our studies may have more adversely affected the inflammatory and 
cellular responses involved in MSC homing as well as bone repair.  Low dose radiation has been 
shown to initially increase inflammatory markers and then subside within several days. This 




regenerative processes in low dose radiation models. However, in larger dose per fraction 
protocols as administered in this study, inflammatory markers have been shown to persist at high 
levels for up to 26 weeks (76). It has been shown that less than 12.5% of MSCs injected 
systematically actually reach bones irradiated with one fraction of 26.5 Gy (162).  Furthermore, 
another study in bone after irradiation using a single dose of 30 Gy revealed decreased MSC 
viability from 70% at 2 hours to less than 40% a week after IO MSC injection (163). Although 
the inflammatory processes may allow for the homing of MSCs, the excessive production of 
inflammatory mediators may have had deleterious affect on the viability of MSCs. Our high dose 
radiation model also showed large areas of sclerosis, necrosis, as well as necrotic bone marrow 
resulting in an environment where normal dynamic bone remodeling is not occurring. Vascular 
ischemia, fibrosis and injury of irradiated tissue induced by large doses of irradiation in this 
study could be hindering the ability of MSCs to survive in this environment to the lack of vital 
nutrients and oxygen from the blood (164).  Further studies are needed to assess the viability of 
MSCs after high dose radiation immediately following implantation as well as several weeks 
afterward. 
 
 Although GFP expressing cells can help track the migration and engraftment of MSCs, 
we evaluated bone volume, TRAP, alizarin, and alkaline phosphatase expression and to further 
confirm the lack of bone repair with MSCs. Again, no differences were observed between any of 
the groups.  There were significant decreases between a normal control bone and the expression 
of TRAP, Alizarin and alkaline phosphatase in the SRT only, IO and IV groups. These 
significant decreases observed in these markers of bone formation indicate that the large dose of 




received MSCs.  The normal tissue tolerance of bone is approximately 20 Gy. The BED in this 
study far exceeds this threshold thus further confirming the lack of bone repair in the MSC 
groups and clearly shows the adverse effects (osteosclerosis, marrow necrosis, lacking Alizarin 
and AP expression) to bone in a high dose model as compared to lower dose models in which 
alkaline phosphatase and alizarin levels were elevated after MSC injection (89, 90).  
 
 The secondary aim of this study was to determine whether allogeneic MSCs administered 
by either IO or IV enhanced tumor progression or recurrence after treatment with SRT. Several 
studies have shown that MSCs can home to existing tumors and promote tumor growth at local 
and distant metastatic sites (101, 152). Therefore, if SRT did not effectively achieve local tumor 
control, then the use of MSCs could potentially promote the growth and progression of OSA. 
Percent tumor necrosis and luciferase expression were used as an indirect measure of the tumor 
viability and compared between groups. The SRT only group had the highest percent tumor 
necrosis of 95.8 percent with one recurrence in luciferase expression, which was comparable to 
similar studies in Chapter 3. There were no differences between the SRT only and the IO group. 
Interestingly, there was a significant difference in tumor necrosis between the SRT only and the 
IV group. Luciferase expression also recurred in three animals in the IV group. Although the 
data suggests the IV group had a higher percentage of viable tumors, the high variability of 
tumor necrosis and limited number of animals make it difficult to make an accurate conclusion 
as to whether this finding is directly attributed to the MSCs. Furthermore, the lack of GFP 
expressing cells in the tumor regions indicates the MSCs were not present at the time of 
sacrifice. However, it is possible that MSCs may have secreted other tumor promoting factors 




resulted in decreased tumor necrosis in the IV group (153). Further investigation is needed to 
elucidate this possibility. It is also feasible that the irradiated environment hindered MSCs 
survival thus blocking their ability to secrete tumor-promoting factors and hindering their ability 
to promote tumor growth. Evaluation of distant lesions after MSC injection by gross observation 
revealed no metastases in the lungs or adjacent bones. Previous studies have shown MSCs can 
increase progression of distant OSA metastases using a highly metastatic OSA cell line (152). 
The use of a highly metastatic cell line may better evaluate role of MSCs in local and distant 
tumor progression when using SRT as a primary means of local tumor control.  
 
 A limitation of this study is that SRT was administered to the entire femur rather than just 
the tumor lesion. Irradiating the entire bone was required due to the small size of the rat femur 
and the limitations of the linear accelerator.  In clinical canine OSA cases, the tumor lesion is 
irradiated with acceptable margins to the normal bone. The remaining bone is spared from 
irradiation, thus leaving a source of osteogenic progenitor cells, marrow and vascularity 
immediately adjoining the irradiated bone. It is unlikely that local tumor control can be achieved 
at total radiation doses in the 20-25 Gy range to permit sparing of the normal bone immediately 
surrounding the tumor.  For successful MSC engraftment and osteogenic differentiation, a 
healthy vascular supply, physical microenvironment, growth factors and cytokines are required.  
The adverse effects of high dose radiation administered to the entire bone in this study are 
consequently causing bone marrow necrosis as observed in the histology. These effects are likely 
limiting the viability of systematically injected and IO MSCs to promote new bone growth (165). 
A study previously discussed administered radiation doses as high as 60 Gy and showed 




of the implanted femur had been irradiated and submerged with MSCs (102). Limiting the 
radiation field with SRT to the tumor with acceptable margins rather than the entire bone may 
provide a better environment for MSC engraftment. This would also increase the recruitment of 
host osteoprogenitor cells from the surrounding normal bone as well as vascular ingrowth that 
would result in new bone formation at the site of irradiation. Optimizing SRT to ablate the tumor 
region or using SRT in a partial section of normal bone in a larger rabbit or sheep animal model 
would help to further evaluate this hypothesis. 
 
 Another limitation is that this study used undifferentiated MSCs and it’s unclear what 
percentage of these cells could potentially differentiate into osteoblasts. There are a number of 
studies that suggest that priming MSCs towards a specific lineage (e.g. osteoblasts or 
chondrocytes) before implantation may promote more bone growth than MSCs in their native 
state (166, 167). Thus, priming MSCs before implantation in this SRT model may promote bone 
growth over undifferentiated MSCs. A recent study showed that chondrogenic priming of MSCs 
resulted in more bone repair and regeneration than osteogenic priming (168). Unlike osteoblasts, 
which induce bone growth through intramembranous ossification, chondrocytes can induce bone 
growth through endochondral ossification.  This process carried is out in a low oxygen and 
avascular environment similar to that of a bone after radiation therapy. Therefore, 
chondrogenically primed MSCs could be advantageous in irradiated bone over osteogenically 
primed or undifferentiated MSCs due to their ability to promote bone formation in areas of low 





 With consideration for future studies evaluating the potential role of MSCs for bone 
regeneration in SRT treated tumor affected bone, SRT will first have to be optimized to target 
the tumor lesion itself while sparing as much normal bone as possible.  Leaving the remaining 
normal bone relatively unaffected from the radiation will then allow the evaluation of bone 
promoting strategies after SRT.  The administration of MSCs may then be able to home to the 
affected bone and induce bone growth. Repeated administration of MSCs may also help further 
enhance this effect. Predifferentiating MSCs, particularly down the chondrogenic lineage, could 
potentially promote more bone formation in irradiated areas. Furthermore, genetically modifying 
MSCs to express bone promoting genes or in combinations with growth factors, parathyroid 
hormone and bone promoting biomaterials may further deem efficacious. The addition of 
bisphosphonates, which inhibit tumor associated bone resorption as well as drugs that can reduce 
the dose needed to achieve tumor control could further benefit bone formation strategies. These 
future directions can then be translated into clinical canine cases and ultimately into humans.  
 
 In summary, we evaluated the ability of MSCs to regenerate bone growth after SRT as 
well as the possibility that MSCs will promote tumor growth. Our results indicate that there was 
no new bone formation in the IV or IO MSC treatment groups when compared to the control 
group (SRT only). Lack of new bone formation is most likely due to the effects of high dose 
radiation creating an unfavorable environment for survival and differentiation of administered 







Chapter 6: Summary of Findings and Future Directions 
 
Chapter 2 was devoted to the development an orthotopic rat model of canine osteosarcoma. We 
hypothesized that canine OSA cells injected into the tibias and femurs of rats would engraft and 
exhibit predictable progression. As expected, tumors engrafted in both locations, predictably 
progressed and exhibited similar characteristics to clinical cases. These data supported our 
hypothesis and described the first rat model of orthotopically located canine OSA that can be 
used for the evaluation of clinically relevant therapeutics for the treatments for this devastating 
disease. 
 
Chapter 3 described the development of techniques to deliver SRT to a femur as well as its 
effectiveness in achieving acceptable percent tumor necrosis in the OSA model described in 
Chapter 2. We hypothesized that SRT could be successfully administered to a rat and would 
result in an increase of percent tumor necrosis. Different total dose and fractionation protocols 
were administered to OSA lesions in rats and tumor necrosis as well as acute effects was 
evaluated. Administration of SRT was feasible and three fractions of 12 Gy was determined to be 
the optimal protocol to achieve greater than 80% tumor necrosis while minimizing the acute 
radiation effects. These data supported our hypothesis and described the first use of SRT in a rat 
model. Furthermore, it resulted in a viable dosing and fractionation protocol that achieved 
increased tumor necrosis that could be clinically relevant to clinical cases of OSA. 
 
In Chapter 4, mesenchymal stem cells were isolated from the bone marrow and adipose tissue 
from GFP expressing rats. We hypothesized that these MSCs would exhibit multipotency when 




differentiate into adipocytes, chondrocytes and osteoblasts as well as to express GFP thus 
confirming our hypothesis. The establishment of this GFP expressing MSC cell line allowed for 
the visualization of these MSCs in histological analysis when evaluating the bone forming 
potential of MSCs.  
 
Chapter 5 evaluated the ability of intravenously or systemically injected MSCs to regenerate 
bone after SRT of OSA in the rat model described herein. We hypothesized that MSCs would 
induce new bone growth and no new bone growth would be observed in animals that did not 
receive MSCs. The results indicated that MSCs did not regenerate new bone growth most likely 
due to the adverse effects of high dose radiation on the entire bone. Although the results did not 
support our hypothesis, this experiment described the first use of MSCs for bone generation 
following SRT in an OSA model.  These results provided a great deal of information including 
potential modification of SRT protocols in future experiments, which could permit MSCs to 
promote bone generation following SRT.  
 
With consideration for future studies evaluating the potential role of MSCs for bone regeneration 
in SRT treated tumor affected bone, SRT will first have to be optimized to target the tumor 
lesion itself while sparing as much normal bone as possible.  Leaving the remaining normal bone 
relatively unaffected from the radiation can allow for the recovery of MSCs in the untreated 
areas of bone. This will also help preserve vasculature, host cells (osteoblasts, osteoclasts, 
progenitor cells, etc) and structural integrity of the existing bone.  The preservation of the 
unaffected bone may allow MSCs to encounter a better environment and subsequently induce 




further enhance this effect. As previously discussed, predifferentiating or sorting MSCs that 
express osteogenic markers, particularly down the chondrogenic lineage, could potentially 
promote more bone formation in irradiated areas. The chondrogenic lineage could lead to 
endochondral bone growth, which is a vital process in bone healing. Furthermore, genetically 
modifying MSCs to express bone promoting genes or in combinations with growth factors, 
parathyroid hormone and bone promoting biomaterials may further deem efficacious. The 
addition of bisphosphonates, which inhibit tumor associated bone resorption as well as drugs that 
can reduce the dose needed to achieve tumor control could further benefit bone formation 
strategies.  Any use of MSCs alone or in combination any of the methods described above in a 
tumor environment would need to be thoroughly evaluated for safety to ensure the treatment is 
not promoting tumor growth or recurrence.  A positive outcome in these future experiments 
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Appendix A: Specific Aim 1 Detailed Protocols and Data 
 
7.1 Cell culture of Abram’s OSA CELLS 
 
1.0 Purpose:  
 
To grow and propagate the Abram’s osteosarcoma cell line in culture 
 
2.0 Scope:  
 
 Applies to the osteosarcoma rat model 
 
3.0 Responsibility:   
 
3.1 It is the responsibility of the ACC MS Lab Director(s), study director or qualified personnel to ensure 
that personnel performing the allograft isolation procedure have received adequate training to perform 
the procedure. 
 
4.0 Reference Documents:  N/A 
    
 
5.0 Definitions:  N/A 
 
6.0 Safety Precautions:   
 





7.1 Materials  
 
7.1.1 Pipettes 
7.1.2 70% Ethanol 
7.1.3 150 cm Cell culture flask 





7.1.5 Culture hood, Incubator 5% CO2 
7.1.6 Microscope 
 
7.2 Reagents  
7.2.1 DMEM + 10% FBS Growth Media 
7.2.2 Trypsin 
 
7.3 Working Reagent Preparation    N/A 
 
7.4 (Test) Procedure 
2.2.12  




7.4.2 Thaw the vial of OSA cells in 37 degrees for 5 minutes 
7.4.3 Carefully pipette out the thawed OSA cells and place them into the cell culture flask 
7.4.4 Add 15mL of media to the flask and place in the incubator overnight 
7.4.5 During the next day, check the cells for adherence to the plate and monitor daily until 
cells become confluent 
7.4.6 Split the cells by aspirating the existing media and adding 2 mLs of Trypsin to the place 
7.4.7 Incubate for ~5 minutes until cells are detached and add ~8 mLs of culture media to the 
flask. 
7.4.8 Distribute in 1 mL increments to additional flasks and add 14 mLs of media to each flask 
for a total volume of 15 mLs 
7.4.9 Incubate until confluent and repeat 7.4.6 to continue cell culture 
 
 7.7  Reporting Results  N/A 
  





































7.2 Osteosarcoma Cell Injections into nude rats 
 
1.0 Purpose:  
 
To inoculate nude rats with the Abram’s OSA cell line 
 
2.0 Scope:  
 
 Applies to the the osteosarcoma rat model 
 
3.0 Responsibility:   
 
3.1 It is the responsibility of the ACC MS Lab Director(s), study director or qualified personnel to ensure 
that personnel performing the allograft isolation procedure have received adequate training to perform 
the procedure. 
 
4.0 Reference Documents:  N/A 
    
 
5.0 Definitions:  N/A 
 
6.0 Safety Precautions:   
 





7.1 Materials  
 
7.1.1 24 G Needles 
7.1.2 70% Ethanol & Betadine 
7.1.3 Cultured Abram’s OSA cells 
7.1.4 5% Isofluroane  
7.1.5 Sterile Gloves, mask, cap, and scrubs 




4.1.1 Heating pad 
4.1.2 Surgical Table 
 
4.2 Reagents  
4.2.1 N/A 
 
4.3 Working Reagent Preparation    N/A 
 
4.4 (Test) Procedure 
2.2.13  
4.4.1 Sterilize the surgical table 
4.4.2 Prepare enough cells as outlined in the OSA culture SOP to inject 1e^6 Cells per rat in 
50ul of media 




4.4.4 Place the rat on the surgical table and clean the limb to be injected three times with 
ethanol and betadine 
4.4.5 Insert a 22G needle into the femur at level of the trochantic fossa and advance distally 
within the medullary canal with a rotating motion to the distal metaphysis and then 
withdraw. This needle cannot be used for injection because it is clogged with a bone 
plug. 
4.4.6 Insert a second 22G needle into the femur at level of the trochantic fossa and advance 
distally to the desired inoculation area. Attach a 10mL needed filled with the OSA cells 
to the 22G needle inserted into the animal. Inject the cells very slowly to prevent 
embolism.  
4.4.7 Once cells have been injected, remove the needle slowly and discard. 
4.4.8 Return the rat to its cage and observe until it has recovered. 
4.4.9 Repeat with the remaining rats 
 
 7.7  Reporting Results N/A 
  




































7.3 PYD ELISA 
 
1.0 Purpose:  
 
To analyze the urine concentrations from rats 
 
2.0 Scope:  
 
 Applies to the osteosarcoma rat model 
 
3.0 Responsibility:   
 
3.1 It is the responsibility of the ACC MS Lab Director(s), study director or qualified personnel to ensure 
that personnel performing the allograft isolation procedure have received adequate training to perform 
the procedure. 
 
4.0 Reference Documents:  N/A 
    
 
5.0 Definitions:  N/A 
 
6.0 Safety Precautions:   
 





7.1 Materials  
 
7.1.1 Urine Samples 
7.1.2 Quidel PYD Urine ELISA Kit  




4.1.1 Plate Reader 
 
5.1 Reagents  
5.1.1 PBS, ddH20 
 
5.2 Working Reagent Preparation    N/A 
 
5.3 (Test) Procedure 
5.3.1 Dilute Standards and Controls 1:10 with Assay Buffer  
5.3.2 Dilute urine samples 1:50 in assay buffer. 
5.3.3 Remove coated strips from the pouch and place in the provided holding tray. 
5.3.4 Label wells to identify samples 
5.3.5 Add 50 µL diluted Standard, Control or sample to each well within 30 minutes. 
5.3.6 Prepare Enzyme Conjugate within 2 hours of use by reconstituting the vial of Enzyme 
Conjugate with 7 mL of the assay buffer and keep cold until ready for use. 
5.3.7 Add 100 µL of reconstituted Enzyme Conjugate to each well and cover with the cover 
strip. 




5.3.9 Prepare Working Substrate Solution within 1 hour of use by adding the Substrate Tablet 
into each required bottle. Allow 30–60 minutes for tablet(s) to dissolve. Vortex 
vigorously to mix. 
5.3.10 Prepare required amount of 1X wash buffer by diluting 10X wash buffer with ddH20. 
Add 250 µL of the wash buffer to each well and manually invert/empty strips to remove 
buffer. Repeat two more times for a total of three washes. Vigorously blot the strips dry 
on paper towels after the last wash. While strips are inverted, carefully wipe bottom of 
strips with a lint-free paper towel to ensure that the bottom of the strips are clean.  
5.3.11 Add 150 µL of the working substrate solution to each well and incubate for 60 minutes.   
5.3.12 Add 100 µL of stop solution to each well.  
5.3.13 Read the optical density at 405 nm within 15 minutes of adding the stop solution. 
5.3.14 The computer will calculate the concentrations and output them to an excel sheet. 
 7.7  Reporting Results N/A 
  


































































































































Appendix B: Specific Aim 2 Protocols and Data 
 























































































































































Appendix C: Specific Aim 3 Detailed Protocols and Data 
 
9.1 Isolation of bone marrow rat mesenchymal stem cells that express GFP 
 
1.0 Purpose:  
 
To isolate bone marrow mesenchymal stem cells from rats 
 
2.0 Scope:  
 
 Applies to the MSC injections in the osteosarcoma rat model 
 
3.0 Responsibility:   
 
3.1 It is the responsibility of the ACC MS Lab Director(s), study director or qualified personnel to ensure 
that personnel performing the allograft isolation procedure have received adequate training to perform 
the procedure. 
 
4.0 Reference Documents:  N/A 
    
 
5.0 Definitions:  N/A 
 
6.0 Safety Precautions:   
 





7.1 Materials  
 
7.1.1 At least four GFP expressing rats 
7.1.2 Pipettes, centrifuge, syringes 
7.1.3 70% Ethanol, PBS, collagenase 
7.1.4 150 cm Cell culture flask 





7.1.6 Culture hood, Incubator 5% CO2 
7.1.7 Microscope 
7.1.8 Surgical table 
7.1.9 Surgical scissors and a scalpel 
7.1.10 Isofluorane induction chamber 
 
7.2 Reagents  
7.2.1 DMEM + 15% FBS Growth Media 
7.2.2 Trypsin 
 





7.4 (Test) Procedure 
2.2.14  
7.4.1 Sterilize the hood, Warm media to 37 degrees for 15 minutes 
7.4.2 Anesthetize rats and euthanize via cardiac puncture 
7.4.3 Use the scissors to cut away skin around each leg being sure to be sterile and use ethanol 
to sterilize the skin before cutting. 
7.4.4 Once skin is removed, disarticulate the femurs and place them in a cell culuture plate in 
growth media 
7.4.5 Remove the distal and proximal ends of each femur and flush the inner marrow cavity 
with growth media using a 16-gauge needle attached to a syringe into a collection tube. 
7.4.6 Once all marrow has been aspirated from all femurs, disperse the cells using 18 and 20 
gauge needles. 
7.4.7 Centrifuge dispersed cells at 1000 RPM for 5 minutes 
7.4.8 Remove the supernatant and then resuspend the cell pellet with growth media 
7.4.9 Add the cells to the culture flask and place in the incubator overnight 
7.4.10 During the next day, check the cells for adherence to the plate and monitor daily until 
cells become confluent 
7.4.11 Split the cells by aspirating the existing media and adding 2 mLs of Trypsin to the plate 
7.4.12 Incubate for ~5 minutes until cells are detached and add ~8 mLs of culture media to the 
flask. 
7.4.13 Distribute in 1 mL increments to additional flasks and add 14 Mls of media to each flask 
for a total volume of 15 Mls 
7.4.14 Incubate until confluent and repeat 7.4.10 to continue cell culture 
 
 7.7  Reporting Results  N/A 
  





























To isolate adipose mesenchymal stem cells from rats 
 
1.0 Scope:  
 
 Applies to the MSC injections in the osteosarcoma rat model 
 
2.0 Responsibility:   
 
2.1 It is the responsibility of the ACC MS Lab Director(s), study director or qualified personnel to ensure 
that personnel performing the allograft isolation procedure have received adequate training to perform 
the procedure. 
 
4.0 Reference Documents:  N/A 
    
 
5.0 Definitions:  N/A 
 
6.0 Safety Precautions:   
 





7.1 Materials  
 
7.1.1 Two GFP expressing rats 
7.1.2 Pipettes, centrifuge, syringes 
7.1.3 70% Ethanol, PBS, collagenase 
7.1.4 150 cm Cell culture flask 





7.1.6 Culture hood, Incubator 5% CO2 
7.1.7 Microscope 
7.1.8 Surgical table 
7.1.9 Surgical scissors and a scalpel 
7.1.10 Isofluorane induction chamber 
 
7.2 Reagents  
7.2.1 DMEM + 15% FBS Growth Media 
7.2.2 Trypsin 
 
7.3 Working Reagent Preparation    N/A 
 
7.4 (Test) Procedure 
2.2.15  




7.4.2 Anesthetize rats and euthanize via cardiac puncture 
7.4.3 Use the scissors to make an incision in the abdominal area and remove excess skin to 
avoid contamination 
7.4.4 Use the scalpel to remove the Epididymal fat pad and place it a tube with PBS 
7.4.5 Once all fat is collected from both mice, add an equal volume of collagenase to the PBS 
and place in the incubator until the solution become homogenous 
7.4.6 Centrifuge the collagenase solution at 1,200 RPM for 5 minutes 
7.4.7 Remove the supernatant and then resuspend the cell pellet with growth media 
7.4.8 Add the cells to the culture flask and place in the incubator overnight 
7.4.9 During the next day, check the cells for adherence to the plate and monitor daily until 
cells become confluent 
7.4.10 Split the cells by aspirating the existing media and adding 2 mLs of Trypsin to the plate 
7.4.11 Incubate for ~5 minutes until cells are detached and add ~8 mLs of culture media to the 
flask. 
7.4.12 Distribute in 1 mL increments to additional flasks and add 14 Mls of media to each flask 
for a total volume of 15 Mls 
7.4.13 Incubate until confluent and repeat 7.4.10 to continue cell culture 
 
 7.7  Reporting Results  N/A 
  
































9.3 Cell culture of bone and adipose rat mesenchymal Stem cells 
 
1.0 Purpose:  
 
To grow and propagate the adipose or bone marrow derived mesenchymal stem cells in culture 
 
2.0 Scope:  
 
 Applies to the MSC injections in the osteosarcoma rat model 
 
3.0 Responsibility:   
 
3.1 It is the responsibility of the ACC MS Lab Director(s), study director or qualified personnel to ensure 
that personnel performing the allograft isolation procedure have received adequate training to perform 
the procedure. 
 
4.0 Reference Documents:  N/A 
    
 
5.0 Definitions:  N/A 
 
6.0 Safety Precautions:   
 





7.1 Materials  
 
7.1.1 Pipettes 
7.1.2 70% Ethanol 
7.1.3 150 cm Cell culture flask 





7.1.5 Culture hood, Incubator 5% CO2 
7.1.6 Microscope 
 
7.2 Reagents  
7.2.1 DMEM + 10% FBS Growth Media 
7.2.2 Trypsin 
 
7.3 Working Reagent Preparation    N/A 
 
7.4 (Test) Procedure 
2.2.16  
7.4.1 Sterilize the hood, Warm media to 37 degrees for 15 minutes 
7.4.2 Thaw the vial of MSCs in 37 degrees for 5 minutes 
7.4.3 Carefully pipette out the thawed OSA cells and place them into the cell culture flask 




7.4.5 During the next day, check the cells for adherence to the plate and monitor daily until 
cells become confluent 
7.4.6 Split the cells by aspirating the existing media and adding 2 mLs of Trypsin to the place 
7.4.7 Incubate for ~5 minutes until cells are detached and add ~8 mLs of culture media to the 
flask. 
7.4.8 Distribute in 1 mL increments to additional flasks and add 14 Mls of media to each flask 
for a total volume of 15 Mls 
7.4.9 Incubate until confluent and repeat 7.4.6 to continue cell culture 
 
 7.7  Reporting Results  N/A 
  





































Appendix D: Specific Aim 4 Supplementary Protocols and Data 
10.1 Calculation of Bone Volume via microCT 
Rat femurs were scanned with a Scanco uCT40 (Brüttisellen, Switzerland) at a 10-micron 
resolution. Bone volume was then determined as follows with the Scanco Image Analysis 
Software: 
1) Total bone volume of each femur was determined using the femur as the volume of interest (VOI) 
2) Normalized VOI based using the smallest tumor as the reference VOI and calculated for each 
femur (Figure 1A) 
3) Normalized VOI based on three region of equal areas of volume (100 X 100 X 200 slices) around 
the tumor as shown in Figure 1B). The same regions were used to calculate bone volume in each 
femur. 
Volumes were then compiled for each group, outputted to an excel file and evaluated for 








10.2 Osteocalcin ELISA 
 
4.0 Purpose:  
 
To analyze the serum osteocalcin in rats 
 
5.0 Scope:  
 
 Applies to the osteosarcoma rat model 
 
6.0 Responsibility:   
 
6.1 It is the responsibility of the ACC MS Lab Director(s), study director or qualified personnel to ensure 
that personnel performing the allograft isolation procedure have received adequate training to perform 
the procedure. 
 
8.0 Reference Documents:  N/A 
    
 
9.0 Definitions:  N/A 
 
10.0 Safety Precautions:   
 





11.1 Materials  
 
11.1.1 Serum Samples 
11.1.2 Biomdical Technologies Rat Osteocalcin ELISA (BT-490) 




4.1.2 Plate Reader 
 
6.1 Reagents  
6.1.1 PBS, ddH20 
 
6.2 Working Reagent Preparation    N/A 
 
6.3 (Test) Procedure 
6.3.1 Remove ELISA plate from re-sealable bag.  
6.3.2 Dilute the stock standard (100ng/ml) in polypropylene tubes with sample buffer to give 
six or seven standards in the range of 0.25 to 20ng/ml. (0.33, 1.0, 2.5, 5.0, 10 and 
20ng/ml) 
6.3.3 Dilute the serum samples 1:10 in the sample buffer. 
6.3.4 Pipet 25ul of sample buffer (Blank), Standards, Controls and Unknowns into labeled 
wells followed by 100ul of osteocalcin antiserum in each well. 
6.3.5 Seal the plate with the provided cover slip. 




6.3.7 Aspirate wells completely and wash the plate 3 to 5 times with 300 ul per well with the 
provided Phosphate-Saline wash buffer.   
6.3.8 Add 100ul of the diluted Donkey anti-Goat IgG Peroxidase to each well. 
6.3.9 Incubate at room temperature for 1 hour.  
6.3.10 Mix one volume of TMB solution with one volume of Hydrogen Peroxide solution  
(provided). 
6.3.11 Wash the plate as in step 6.3.7.   
6.3.12 Immediately add 100ul of substrate mix to all wells and incubate in the dark at room 
temperature for 30 minutes.  
6.3.13 Add 100ul of Stop Solution to each well and swirl.  
6.3.14 Measure absorbance at 450nm within 15 minutes. 
6.3.15 The computer will calculate the concentrations and output them to an excel sheet. 
 7.7  Reporting Results N/A 
  










































































































































































































































































































 The design of a statistical study must be carefully planned prior to execution to ensure 
that the desired effect can be observed using a particular sample size. A power analysis is usually 
conducted to determine the sample size required to reject the null hypothesis if in fact the null 
hypothesis is false. An insufficient power analysis can result in two common types of statistical 
errors. The first is a Type 1 error, which occurs when the null hypothesis is rejected when it is 
actually true (False Positive). The second is a Type 2 error, where the alternative hypothesis is 
rejected when it is actually true (False Negative). Determining an adequately powered 
experiment can minimize these errors from occurring.  
 
 Before conducting a power analysis, certain parameters must first be determined about 
the experiment. First, a hypothesis must be devised that aims to detect differences in two or more 
populations. The investigator must determine the effect size (ES), or the desired effect that is 
expected in the hypothesis. For example, “Does the addition of chemotherapy in cancer patients 
receiving radiation therapy increase survival?” A 1% increase in survival may not be clinically 
relevant; however, a 25% increase may indicate a response to treatment. It is important to note 
that smaller treatment effects require larger sample sizes while larger treatment effects can 
reduce the sample size. Effect size is usually derived from previously published data or pilot 
experiments. The equation for effect size is depicted in Equation 1 (1). It consists of the 
difference in means (u1 – u2) divided by the pooled standard deviation between the means. Next, 
power (1-b) and significance (a) levels must be determined. The power is the probability of 




commonly, a power level of 80% is used in experimental design. The significance level, often 
chosen to be a = 0.05, is the probability of concluding the treatment is effective when it is 
actually not effective. The power level can increased and the alpha level can be decreased, but 
changing these parameters can result in large increases in the sample size, which may not be 
feasible. Once these parameters have been established, a power analysis can be conducted to 
determine the sample size by using the follow equations:  
 
ES = Effect Size = (u1–u2)/spooled (1) 
 
Equation 2: Effect size equation where U1 and U2 are means and s is standard deviation. S1 and S2 are the standard 
deviation of each mean. 
 
Sample size = n = (Z1-a + Z1-b)2 (s1+s2)2 / (u1-u2)2 (1) 
  
Equation 3: Power equation for determining sample size. Values for Za and Z1-b can be found in Table 2 in the Appendix 
for specific power and significance levels. For the calculations described herein, Z1-b = 0.823 (80%) and Za = 1.960 (5%). 
 
 A power analysis is usually calculated prior to conducting the experiment; however, a 
post-hoc analysis may be conducted after an experiment has ended to determine if the study was 
adequately powered. This can be useful in a variety of situations particularly when sample size 
cannot necessarily be controlled (e.g. when using wild animals). In a post-hoc analysis, the 
sample and effect sizes are obtained from the data collected. The equation for power as follows: 
 










Equation 4: Power equation using ES = effect size and n = sample size. The resultant δ (power) can be found 
in Table 2 in the appendix to determine power. 
 
 The following is a post-hoc power analysis on the experiments examining the bone 
regeneration and tumor promoting potential of mesenchymal stem cells (MSCs) after stereotactic 
radiotherapy (SRT) for the treatment of osteosarcoma (OSA). The primary aim was to determine 
if MSCs increased bone volume, PYD, osteocalcin, alizarin, alkaline phosphatase (ALP), and 
TRAP levels. Increases in these were expected after the administration of (MSCs). The 
secondary aim was to determine if MSCs induced tumor growth by decreasing tumor necrosis. 
Effect sizes for each experiment were determined using data from the experiments. The power 
was then calculated using the equations above and verified with the G*Power computer 
application (2).  Once power was determined, a new power analysis was performed using the 
newly defined effect sizes to determine the sample size required for a new and more adequately 
























Post-hoc Power Analysis 
 
Normalized Mean Bone Volume 
 
 
Figure 39: Normalized mean bone volume from MSC experiments (n=8 per group, n=24 total). 
 
The graph in Figure 1 represents the normalized mean bone volume between the control group 
(SRT Only, Mean: 0.69 +/-0.17 mm3) and the animals that received MSCs through Intravenous 
(IV, Mean: 0.84 +/- 0.19 mm3) or Intraosseous (IO, Mean: 0.86 +/-0.16 mm3) injection. MSCs 
were expected to increase bone volume; however, there were no differences observed between 
groups. Means were used to calculate the effect sizes and power as follows:  
IV versus SRT Only: 
 Effect size = |(.69 – .84)| / 0.18 = 0.83 
 
Using the above effect size and Equation 3, the power was calculated as follows:  
 























The reference value for δ = 1.66 in Table 2 in the Appendix resulted in a power of approximately 
47.50%.   
 
IO versus SRT Only: 
 
Effect size = |(.69 – .86)| / 0.19 = 1.02 
 
Using the above effect size and Equation 3, the power was calculated as follows:  
 
δ = power = ES √(n/2) = 2.10 √(8/2) = 2.05 
 
The reference value for δ = 4.20 in Table 2 in the Appendix resulted in a power of approximately 




















Figure 40: Mean osteocalcin levels between each group. (n=8 per group, n=24 total). 
The graph in Figure 2 depicts mean osteocalcin levels between the baseline control group (SRT 
Only, Mean: 12.75 +/- 0.02 ng/ml) and the animals that received MSCs through Intravenous (IV, 
Mean: 12.27 +/- 0.7 ng/ml) or Intraosseous (IO, Mean: 13.31 +/- 0.74 ng/ml) injection. In this 
study, the goal was to determine if administering MSCs at week 4 would increase osteocalcin 
levels. There were no differences between baseline (SRT only) and the IO or IV groups. The 
means were used to calculate the effect sizes and power as follows:   
IV versus SRT Only: 
Effect size = |(12.75 – 12.27)| / 0.97 = 0.83 
Using the above effect size and Equation 3, the power was calculated as follows:  






The reference value for δ = 1.66 in Table 2 in the Appendix resulted in a power of approximately 
36.00%.   
 
IO versus SRT Only: 
Effect size = |(13.31 – 12.75)| / 0.52 = 1.06 
 
Using the above effect size and Equation 3, the power was calculated as follows:  
δ = power = ES √(n/2) = 1.06 √(8/2) = 1.76 
 
The reference value for δ = 1.66 in Table 2 in the Appendix resulted in a power of approximately 



























Figure 41: Mean PYD levels between each group. (n=8 per group, n=24 total). 
The graph in Figure 3 depicts changes in PYD levels throughout the duration of the experiment 
to assess the effects of MSC administration on PYD levels. In this study, the goal was to 
determine if administering MSCs at week 4 would increase PYD levels. There were no statistical 
differences between the MSC groups and the SRT Only group.  To determine effect sizes and 
power, the SRT only mean (4.02 +/- 0.08) was compared to the IV (3.99 +/- 0.15) and IO (3.92 
+/- 0.12) means using Equation 1 as follows:  
IV versus SRT Only: 























Using the above effect size and Equation 3, the power was calculated as follows:  
 
δ = power = ES √(n/2) = 0.25 √(8/2) = 0.50 
The reference value for δ = 0.50 in Table 2 in the Appendix resulted in a power of approximately 
12.00%.   
 
IO versus SRT Only 
Effect size = |(4.02 – 3.92)| / 0.10 = 1.00 
 
Using the above effect size and Equation 3, the power was calculated as follows:  
δ = power = ES √ (n/2) = 1 √ (8/2) = 2 
 
The reference value for δ = 2.00 in Table 2 in the Appendix resulted in a power of approximately 
















Bone Marker Expression 
Figure 42: Mean Alizarin, TRAP and ALP levels between groups (n=8 per group). 
The graph in Figure 4 depicts Alizarin, TRAP and Alkaline Phosphatase expression in each 
group as compared to the SRT only group. MSCs were expected to increase these levels above 
the SRT only group. No statistically significant changes were observed. The means in the SRT 
only and MSC groups are as follows: 
Alizarin IO: 3.92 +/- 3.80 % 
Alizarin IV: 6.04 +/- 4.16 
Alizarin SRT: 4.89 +/- 3.29 % 
TRAP IO: 0.07 +/- 0.07 % 
TRAP IV: .21 +/- 0.11 
TRAP SRT: 0.12 +/- 0.16% 
Alkaline Phosphatase IO: 0.21 +/- 0.28 % 
Alkaline Phosphatase IV: 0.17 +/- 0.18 % 
































Using these figures, effect sizes were calculated using Equation 1 as follows for the IV versus 
SRT Only groups: 
ALP Effect size = |(1.31 – 0.17)| / 0.67 = 1.69 
TRAP Effect size = |(0.12 – 0.21)| /0.13  = 0.65 
Alizarin Effect Size = |(4.89 – 6.04)| / 3.75  = 0.30 
 
Using the above effect sizes and Equation 3, power was calculated for the IV versus SRT only 
groups:  
(ALP) δ = power = ES √ (n/2) = 1.69√(8/2) = 1.76 
(TRAP) δ = power = ES √ (n/2) = 0.65 √ (8/2) = 3.38 
(Alizarin) δ = power = ES √ (n/2) = 0/.30 √(8/2) = 0.60 
 
The reference values for δ were found in Table 2 in the Appendix and resulted in power values 
of approximately 14.40% (Alizarin), 34.56% (TRAP), and 94.10% (ALP) for the IV versus SRT 
groups.  
 
For the IO versus SRT Only groups, effect sizes and power were calculated as follows: 
ALP Effect size = |(1.31 – 0.21)| / .28 = 3.92 
TRAP Effect size = |(0.12 – 0.07)| / 0.12= 0.40 
Alizarin Effect Size = |(4.89 – 3.92)| / 0.28 = 0.35 
 
Using the above effect sizes and Equation 3, the power was calculated: 




(TRAP) δ = power = ES √(n/2) = 0.40 √(8/2) = 0.80 
(Alizarin) δ = power = ES √(n/2) = 0.35 √(8/2) = 0.71 
 
The reference values for δ in Table 2 in the Appendix and resulted in powers values of 





































Tumor Necrosis  
Figure 43: Mean percent tumor necrosis between each group (n=8 per group, n=24 total). 
The graph in Figure 5 depicts percent tumor necrosis between the control group and the animals 
that received MSCs through IV or IO injection. This analysis was evaluated to detect decreases 
in tumor necrosis with the addition of MSCs as compared to the SRT only group. The data show 
that there was a statistically significant decrease between the IV (50 +/- 41%) and the SRT only 
group (96 +/- 7%). To that end, a post-hoc power analysis was calculated to determine if the 
sample size was large enough to observe the 48% decrease in tumor necrosis. Then, another 
post-hoc analysis was used to determine the power of observing the IO effect. Using these 
figures, the effect size was calculated using Equation 1 for the SRT versus IV groups:  
Effect size = |(0.96 – 0.50)| / 0.29 = 1.56





δ = power = ES √(n/2) = 1.56√(8/2) = 3.12 
 
The reference value for δ = 3.12 in Table 2 in the Appendix indicated a power of approximately 
90.0%.  
  
For the IO versus SRT Only: 
 
 Effect size = |(0.96 – 0.81)| / 0.29 = 0.711 
 
Using the above effect size and Equation 3, the power was calculated as follows:  
δ = power = ES √(n/2) = 1.56√(8/2) = 1.42 
 
The reference value for δ = 3.12 in Table 2 in the Appendix results in a power of approximately 

























Table 5: Luciferase expression at Week 8 
 Yes No 
SRT Only 1 7 
IV 3 5 
IO 2 6 
 
Bioluminescent imaging was used to evaluate tumor viability between the SRT Only (1/8 = 
12.50%) and the IV (3/8 = 37.5%) and (2/8 = 25.00%) groups at the conclusion of the 
experiment based on a yes or no criteria (Week 8). The binomial proportion post-hoc power 
analysis was evaluated as follows: 
Power for proportions: Zpower = Effect/ √(0.5/n) – 1.64  
Equation 5: Power for proportions 
 
IV versus SRT (25.0% increase):   
Zpower = 0.25/√(0.5/8) – 1.64 = - 0.64 
Power as referenced in Table 4 in the Appendix: 27.00% 
 
IO versus SRT (12.50% increase):  
Zpower = 0.125/√(0.5/8) – 1.64 = - 1.14 









Power Analysis And Experimental Redesign 
 
  
The analysis performed thus far revealed that most of the experiments were underpowered; 
however, it is important to note that in planning the study, effect size and power were calculated 
solely on the bone volume analysis prior to conducting these experiments. To that end, the 
experiments can be redesigned with more relevant effect sizes as well as other modifications that 
result in an adequately powered study that can observe clinically relevant changes. This section 
describes determining new effect sizes for each experiment based on data previously collected or 
from published literature. The sample size was then calculated based on the new effect sizes and 
a power of 80%. The overall experimental design was then modified to account for these changes 

















Bone Volume Power Analysis 
 
The bone volume experiment was originally powered to detect a 20% increase in bone volume. 
This was based off a previous study that showed a mean bone volume increase of 2.1 +/- 0.25 
mm3 with MSCs compared to the control group with a mean bone volume of 1.70 +/-0.10 mm3. 
Using these figures, a ~20% increase in bone volume with MSCs was the desired effect size. No 
differences were seen in this experiment, but it’s important to realize that the previously 
published study did not administer radiation, which has been shown to cause adverse effects to 
bone. It’s quite feasible that the amount of bone formation at the conclusion of these experiments 
may have increased, but to a lesser extent than 20 percent. Therefore, the power calculations 
below were modified to determine the sample size of observing a 5% or 10% increase in bone 
formation. Equation 3 was used to calculate sample sizes assuming 80% power:  
 
For 10% increase: 
 (Z1-a + Z1-b)2 (s1+s2)2 / (u1-u2) =  
(1.96+0.842)2 (0.1225)/(1.7-1.9)2 = 
12 animals per group 
 
For 5% increase: 
 (Z1-a + Z1-b)2 (s1+s2)2 / (u1-u2) =  
(1.96+0.842) 2 (0.1225)/(1.7-1.8) 2 = 
46 animals per group 
 
The results from this power analysis showed that to observe a 10% or 5% increase in bone 





Bone Markers Power Analysis 
 
 
The post-hoc power analysis of the bone formation markers determined that the experiment was 
underpowered. The ideal outcome would result in TRAP, Alizarin and ALP to return to normal 
levels after treatment with MSCs. To achieve these levels, a ~10 fold increase in Alizarin, ~550 
fold increase in TRAP and ~50 fold increase in ALP expression would be needed as shown by 
the control group in Figure 4. Due to the detrimental radiation induced effects to the bone, this 
scenario is highly unlikely. The pervious experiment provided baseline expression levels after 
SRT, but these do not help determine a desired effect size from MSCs. Therefore, a previously 
published study that examined ALP expression in irradiated bone after MSC administration was 
used to determine the effect size. The authors observed a 4-fold increase in ALP levels in the 
irradiated group that received MSCs over the irradiated group that did not receive MSCs (3). 
However, this study used a much lower total radiation dose and only a small section of femur 
was exposed to radiation. As a result, the same 4-fold increase may not be observed in our 
studies. In this power analysis, a smaller 2-fold increase in ALP expression was assumed to be 
the desired effect size. The sample size was then calculated as follows:  
 
(Z1-a + Z1-b) 2 (s1+s2)2 / (u1-u2) =  
(1.96+0.842) 2 (0.28)/(1.13-2.26) 2 = 
4 animals per group 
 
Next, the effect sizes for TRAP and Alizarin were determined. To date, no studies have 
examined Alizarin or TRAP after radiation with or without MSCs in the manner in which these 
experiments were evaluated. Therefore, TRAP and Alizarin were also assumed to have the same 






(Z1-a + Z1-b) 2 (s1+s2)2 / (u1-u2) =  
(1.96+0.842) 2 (0.11)/(0.24-0.12) 2 = 
12 animals per group 
 
Alizarin:  
(Z1-a + Z1-b) 2 (s1+s2)2 / (u1-u2) =  
(1.96+0.842) 2 (4.02)/(4.89-9.78)2 = 





















Osteocalcin Power Analysis 
 
 
The power analysis for the osteocalcin study concluded there was insufficient power to detect 
any differences between groups after MSC administration. It’s important to note that the means 
were approximately the same between groups at each time point thus it’s difficult to determine 
an effect size for a new experiment from these data.  To redesign this experiment in hopes of 
observing an effect, a previously published study was used to determine a new effect size. 
Currently, there are no available studies that have measured serum osteocalcin levels in rats after 
MSC administration. Only one study exists that examined serum osteocalcin levels after 
administration of a bone growth-inducing agent. This study used parathyroid hormone (PTH) to 
increase bone mineral density (4). Although not particularly relevant to MSCs, it provided a 
basis for osteocalcin levels that might be observed if stimulated by a bone growth-inducing 
treatment such as MSCs. This study showed that stimulation with PTH resulted in a 60% 
increase in osteocalcin levels. In our studies, we would not expect to observe the same increase 
in osteocalcin due to the large dose of radiation administered. Therefore, following MSC 
injection, smaller effect sizes of 10% and 30% were assumed as the desired increase in 
osteocalcin over baseline levels (SRT Only). Using these assumed effect sizes, sample size was 
calculated as follows:  
 
For 10% increase: 
 (Z1-a + Z1-b)2 (s1+s2)2 / (u1-u2) =  
(1.96+0.842)2 (1.69)/(12.75-14.50)2 = 
2 animals per group 
 




 (Z1-a + Z1-b)2 (s1+s2)2 / (u1-u2) =  
(1.96+0.842)2 (1.69)/(12.75-16.57)2 = 

























PYD Power Analysis 
 
The PYD power analysis was insignificantly powered to detect the small differences (almost 
identical means) between groups after MSC administration. To redesign this experiment, the 
effect size was determined by using the post-SRT mean (Week 4, 3.63 +/- 0.15) as baseline and 
the pre-SRT mean (Week 2, 4.0 +/- 0.46) as the desired effect.  Using this effect size, it is 
assumed that the administration of MSCs would result in an increase in PYD to pre-SRT levels.  
Using these figures the power was calculated as follows:  
 
50% increase in MSC groups versus SRT: 
 (Z1-a + Z1-b)2 (s1+s2)2 / (u1-u2) =  
(1.96+0.842)2 (0.36)/(4.00-3.63)2 = 

















Tumor Necrosis Power Analysis 
 
The tumor necrosis study determined there was sufficient power to detect a 48% decrease in 
tumor necrosis in the IV group as compared to the SRT only group. Studies have shown that 
tumor necrosis above 80% results in durable tumor control (5). However, tumor necrosis levels 
below 80% often result in poor tumor control (5). This is of particularly importance to the IO 
group, which had a higher mean percent of tumor necrosis (81%+/- 29 %) than the IV group but 
with a large standard deviation. Therefore, being able to detect decreases in tumor necrosis 
below 80% would be of clinical relevance and help determine if the IO MSCs are decreasing 
necrosis to levels that could indicate a lack of tumor control. To determine the power of such an 
experiment, the following equation was used to determine the sample size to observe a decrease 
of 17 +/- 29% in tumor necrosis (79% total) from the SRT only group (96 +/- 7%). 
 
(Z1-a + Z1-b) 2 (s1+s2)2 / (u1-u2) =  
(1.960+0.842) 2 (0.089)/(.96-.79) 2 = 
20 animals per group 
 
These results indicated that increasing the animal numbers to 20 per group would give adequate 










Bioluminescence Power Analysis 
 
 The bioluminescence experiment was underpowered in both the IO and IV comparisons 
to the SRT Only group. In order to achieve the power required to observe the changes in the IV 
(12.5% effect) and IO groups (25.00% effect) from the SRT Only, new sample sizes were 
calculated using Equation 4 solved for n: 
 
Sample size for proportions:  n = 0.5*(0.84– 1.64)2 /Effect Size2 
 
IV versus SRT Only:  
= 0.5*(0.84 + 1.64)2 /0.252 
50 animals per group 
 
IO versus SRT Only:  
= 0.5*(0.84 + 1.64)2 /0.125 
196 animals per group 
 
The results indicate that 50 animals per group would be needed to detect the IV change (25%) 
















Bone Growth Studies 
 
 The power analysis performed using the newly defined effect sizes in the bone growth 
studies yielded a total of 46 animals per group if the desired effect was to observe a 5% increase 
in bone volume. Forty-six animals per group (138 total for 3 groups) is a very large sample size 
to accurately treat with SRT. It can take up to three hours just to plan and deliver the first 
fraction of radiation for each rat. This does not include the extra time required to deliver the 
second and third fractions; therefore, it is not feasible to accurately administer SRT to this large 
sample size.  Increasing the effect level for bone growth to 10% reduces the sample size to a 
more feasible 12 animals per group. Even though the primary aim of the previous study was to 
evaluate bone volume after MSCs administration, it may not be the best tool to evaluate MSC 
activity. Histology revealed that SRT caused detrimental effects to the normal parts of the bone; 
therefore, the potential bone volume changes induced by MSCs may not be visible at the 
conclusion of this short experiment. If the experiment were to be extended, it may be more likely 
to observe an increase in bone volume if the MSCs were inducing bone growth. It’s more 
plausible that at the earlier time points, as evaluated by this experiment, that the molecular levels 
of bone markers (ALP, TRAP and Alizarin) as well as osteocalcin and PYD would be increased 
before any new bone volume could be detected by microCT. Thus bone marker expression may 
be a better indicator of early bone formation with MSCs. Using previously published data and 
the baseline levels observed in this study, it was determined that a 2-fold increase in ALP at the 
end of the experiment would be sufficient to determine an effect mediated by MSCs. This would 
require a sample size of 12 animals per group. No data were available to determine an effect size 




It would be beneficial to perform a pilot study to examine baseline TRAP and Alizarin levels 
after MSC injection in a normal bone using the novel histology techniques performed in these 
studies. This would help provide a better understanding of Alizarin, TRAP and ALP expression 
that might be observed with MSCs and could determine a more appropriate effect size. In the 
osteocalcin experiment, the sample size yielded 4 animals per group; however, it’s important to 
note the small variability and the desired effect (well above the standard deviation of baseline) 
resulted in a small sample size. The desired effect in the osteocalcin assay was based off a 
previously published study that observed significant increases after PTH. A limitation of our 
study was that the detection capabilities of the osteocalcin ELISA were only in the ng/ml range, 
whereas in the PTH study an improved assay was used capable of detecting levels in the pg/ml 
range. Thus, it may be beneficial to run a small pilot experiment with the remaining urine 
samples in the previous experiment with a more sensitive assay to better determine a more 
accurate effect size. The changes in osteocalcin may be much smaller than our assay was capable 
of detecting, yet could still be an important indicator of early bone formation.  In the PYD 
analysis, decreased levels after SRT served as a baseline for the MSC experiments. The effect 
size was determined by the PYD levels immediately before SRT as the potential increase 
induced by MSCs. The power analysis indicated that 12 animals per group would be required to 
adequately power this assay. Therefore, in the bone generation experiments, a sample size of 12 
animals per group would be sufficient to observe the desired effects in the bone markers along 









Tumor Promotion Studies 
 
 In the tumor necrosis power analysis, it was determined that in order to observe an effect 
of 79% or less tumor necrosis that 20 animals per group would be required to achieve adequate 
power.  The increased sample size in this analysis was mediated by the large variability in the 
percent necrosis in the MSC groups. Reducing this variability would in turn decrease the sample 
size while still achieving the desired power level.  A limitation of the tumor necrosis evaluation 
that may be contributing to the large variability is that the samples were stained with 
hematoxylin. Usually, tumor necrosis quantification is evaluated from samples stained with both 
hematoxylin and eosin (H&E). The hematoxylin staining allows for the visualization of the 
nuclei in cells while the eosin staining allows for the visualization of various cellular 
components. The lack of eosin staining created difficultly differentiating between tumor necrosis 
and overall bone necrosis/sclerosis and likely contributed to the variability in the tumor necrosis 
analysis. Staining the samples with both hematoxylin and eosin may provide a more accurate 
analysis of the percent tumor necrosis and may subsequently decrease the variability. Decreasing 
this variability by 10% would decrease the animal numbers to just 10 per group. 
Bioluminescence expression was also used to detect viable OSA cells at the end of the 
experiment; however, the power analysis indicated a very large sample size would be needed to 
observe a 10-25% change in expression. A limitation of bioluminescence is that it has been 
shown to be unreliable in this particular OSA animal model most likely due to the large baseline 
tumor necrosis that can hinder luciferin from sufficiently reaching the viable cells. For this 
reason, bioluminescence was not an accurate indicator of endpoint tumor control. Histology is 
the gold standard for assessing tumor control and requires substantially fewer animals (5). Even 




engraftment and endpoint expression. Most importantly, bioluminescence allows for the 
detection of metastasis that might not otherwise be detectible by gross observation. Considering 




 Taking together the power analysis described herein and the potential limitations of the 
various experiments, a new study would include 20 animals per group. This would provide the 
power to observe the desired increases in bone markers, osteocalcin and PYD levels which 
would most likely be observed at the early time points evaluated in this experiment. This study 
would also be powered to observe tumor necrosis below 80%. This threshold has been shown to 
be a reliable indicator of tumor control in the clinical setting. Levels below 80% have been 
shown to result in tumor control in only ~27% of patients whereas levels above 80% result in 
control in more than 77% of patients (5). Thus, this would provide clinically relevant information 
as to the safety of MSCs through both the IV and IO routes. Although, 20 animals per group 
provide adequate power for these analyses, it would be ideal to reduce this number. As 
previously stated, reducing the variability in the tumor necrosis analysis by properly staining the 
samples could reduce the sample size and while maintaining the desired power. 
 
 In addition to modifying parameters of the current experimental design, other 
modifications may help to better evaluate the bone forming potential of MSCs. For instance, due 
to the limitations of the SRT machine at the time of this experiment, the entire bone was 
irradiated which has been shown to adversely affect the vasculature and osteoprogenitor cells. 




advantage of sparing the existing bone, as done in the clinical setting, leaves the other half of the 
bone less affected by radiation and subsequently spares the vasculature and osteoprogenitor cells.  
Sparing these cells may help the existing bone to heal and allow for a more inhabitable 
environment for the MSCs. To that end, extending the experiment may also be beneficial as it 
could allow more time for the bone to heal and the MSCs to induce bone growth. Repeat 
administration of MSCs could potentially increase their effectiveness. Later time points would 
also allow for better detection of increased bone markers as well as new bone formation. Another 
benefit of extending the experiment is for better for analysis of the tumor promotion studies. If 
MSCs were promoting tumor growth, then extending the study would allow more time for the 
tumors to increase in size and may reduce the variability in tumor necrosis as observed in the 
previous study. Taking together these modification as well as the newly defined effects and 
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Table 6: Power as a function of δ and significance level (a) (1) 
  One-tailed α 
δ .10 .05 .02 .01 
1.00 .26 .17 .09 .06 
1.10 .29 .20 .11 .07 
1.20 .33 .22 .13 .08 
1.30 .37 .26 .15 .10 
1.40 .40 .29 .18 .12 
1.50 .44 .32 .20 .14 
1.60 .48 .36 .23 .17 
1.70 .52 .40 .27 .19 
1.80 .56 .44 .30 .22 
1.90 .60 .48 .34 .25 
2.00 .64 .52 .37 28 
2.10 .68 .56 .41 .32 
2.20 .71 .60 .45 .35 
2.30 .74 .63 .49 .39 
2.40 .78 .67 .53 .43 
2.50 .80 .71 .57 .47 
2.60 .83 .74 .61 .51 
2.70 .85 .77 .65 .55 
2.80 .88 .80 .68 .59 
2.90 .90 .83 .72 .63 
3.00 .91 .95 75 .66 
3.10 .93 .87 .78 .70 
3.20 .94 .89 '81 .73 
3.30 .95 .91 .84 .77 
3.40 .96 .93 .86 .80 
3.50 .97 .94 .88 .82 
3.60 .98 .95 .90 .85 
3.70 .98 .96 .92 .87 
3.80 .98 .97 .93 .89 
3.90 .99 .97 .94 .91 
4.00 .99 .98 .95 .92 
4.10 .99 '98 .96 .94 
4.20 - .99 .97 .95 
4.30 - .99 .98 .96 
4.40 - .99 .98 .97 
4.50 - .99 .99 .97 
4.60 - - .99 .98 
4.70 - - '99 .98 
4.80 - - .99 .99 
4.90 - - - .99 
5.00 - - - .99 
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List of Abbreviations 
 
 
BMP Bone Morphogenetic Protein 
BMP-2 Bone Morphogenetic Protein-2 
CBCT  
CTx 










eGFP Enhanced Green Fluorescent Protein  
GDF Growth Differentiation Factors  
GFP Green Fluorescent Protein  
Gy 
HBSS 
H & E 
Gray 
Hank's Balanced Salt Solution 
Hematoxylin and Eosin Staining 
IACUC  Institutional Animal Care and Use Committee 
IO                   
IORT 
Intraosseous 




Minimum Essential Media 
microCT Micro-computed Tomography  
MSC Mesenchymal Stem Cell 
MTPE Liposome-Encapsulated Muramyl Tripeptide 





PBS  Phosphate Buffered Saline 
PPARg Peroxisome Proliferator-Activated Receptor Gamma 
PYD Pyridinoline  
RPMI 
SD 
Roswell Park Memorial Institute medium 
Standard Deviation 
SRT Stereotactic Radiotherapy 
TGF-b Transforming Growth Factor Beta 
TRAP Tartrate resistant acid phosphatase 
microCT Micro-computed Tomography  
VRTOG 
XRT 
Veterinary Radiation Therapy Oncology Group 
Finely Fractionated Radiotherapy 
 
